## **Appendix 1**

## **RCR Clinical Oncology Syllabus**

#### **Sections**

| 1 | Common competencies for clinical oncology | 2 |
|---|---|---|
|   | Introductory module                       |   |
|   | Oncology emergencies syllabus             |   |
|   | Site-specific learning outcomes           |   |

#### List of abbreviations

Workplace-based assessments

CbD Case-Based Discussion

DORPS Directly Observed assessment of Radiotherapy Planning Skills
DOST Directly Observed assessment of Systemic Therapy skills

mini-CEX Mini-Clinical Evaluation Exercise

MSF Multi-Source Feedback

PS Patient Survey

Others

ARSAC Administration of Radioactive Substances Advisory Committee

BMA British Medical Association
DVH Dose volume histogram

FRCR Fellowship of the Royal College of Radiologists

GMC General Medical Council GMP Good medical practice

ICRU International Commission on Radiation Units and Measurements

IRMER Ionising Radiation (Medical Exposure) Regulations

MDT Multidisciplinary team

NCEPOD National Confidential Enquiry into Patient Outcome and Death

NHSMEE NHS Medical Education England

#### **Domains of Good Medical Practice (GMP) Key**

| 1 | Knowledge, Skills and Performance | 3 | Communication, Partnership and Teamwork |
|---|-----------------------------------|---|---|
| 2 | Safety and Quality                | 4 | Maintaining Trust                       |

It is expected that trainees will maintain knowledge, skills and behaviours previously learned and build on them as they progress through training, so that by CCT they will have developed all of the skills required to work as a consultant in clinical oncology. All of the knowledge, skills and behaviours acquired during intermediate clinical oncology training may be assessed in the Final FRCR examination.

The workplace-based assessment (WpBA) methods shown are those that are appropriate as **possible** methods that could be used to assess each competency. It is expected that competencies will be sampled for assessment and that a variety assessment methods will be used, i.e. it is not expected that all competencies will be assessed nor that where they are assessed, every method will be used. WpBAs should sample across the entire curriculum and be conducted in a timely manner throughout each clinical attachment (i.e. generally spread evenly through training and not all completed in the final weeks of an attachment). This document should be used in conjunction with the ARCP Decision Aid (Curriculum Section 5.5, p18)

## 1 Common competencies for clinical oncology

## Underpinning attitudes and behaviours

Common competencies identified in this section are generic competencies that are required by clinical oncologists. They build upon each area of competence which a trainee has acquired during core medical training. It is recognised that for many of the competences outlined there is a maturation process whereby the doctor becomes more adept and skilled as his/her career and experience progresses.

All the clinical learning outcomes listed in this curriculum are underpinned by appropriate attitudes and behaviours. These are drawn from Good Medical Practice (GMP).

#### 1.1 Personal behaviour

To demonstrate the behaviours that will enable the doctor to become a senior leader able to deal with complex situations and difficult behaviours and attitudes.

To work increasingly effectively with many teams and to be known to put the quality and safety of patient care as a prime objective

To demonstrate the attributes of someone who is trusted to be able to manage complex human, legal and ethical problem.

To be someone who is trusted and is known to act fairly in all situations

| Knowledge   | Assessment<br>Methods                 | GMP   |
|---|---------------------------------------|-------|
| Defines the concept of modern medical professionalism   | CbD                                   | 1     |
| Outlines the relevance of professional bodies (Royal Colleges, NHSMEE, GMC, Postgraduate Deaneries, BMA, medical defence societies, etc)  | CbD                                   | 1     |
| Skills  |                                       |       |
| Practises with professionalism, showing:  integrity  compassion  altruism  continuous improvement  aspiration to excellence  respect of cultural and ethnic diversity  regard to the principles of equity | CbD, mini-CEX,<br>MSF, Patient Survey | 1,2,4 |
| Works in partnership with patients and members of the wider healthcare team   | CbD, mini-CEX,<br>MSF                 | 3     |
| Liaises with colleagues to plan and implement work rotas  | MSF                                   | 3     |
| Promotes awareness of the doctor's role in utilising healthcare resources optimally and within defined resource constraints   | CbD, mini-CEX,<br>MSF                 | 1,3   |
| Recognises and responds appropriately to unprofessional behaviour in others   | CbD                                   | 1     |

| Behaviour   |   |  |                      |
|---|---|--|----------------------|
|   | ersonal beliefs and biases and understand their impact  | CbD, mini-CEX,   | 1                    |
|   | y of health services  | MSF  |                      |
| · · · · · · · · · · · · · · · · · · ·   |   | CbD, mini-CEX,<br>MSF                                    | 1                    |
| Uses all healt  | Uses all healthcare resources prudently and appropriately   |  | 1,2                  |
| Improves clini  | cal leadership and management skill   | CbD, mini-CEX  | 1                    |
| Recognises s and regulatory   | ituations when it is appropriate to involve professional y bodies   | CbD, mini-CEX  | 1                    |
| Acts as a lead  | der, mentor, educator and role model where appropriate  | CbD, mini-CEX,<br>MSF                                    | 1                    |
| Removed     Accepts ment professional compared in the com | eal with inappropriate patient and family behaviour espect the rights of children, elderly, people with physical, ental, learning or communication difficulties dopt an approach to eliminate discrimination against tients from diverse backgrounds including age, gender, ce, culture, disability, spirituality and sexuality acce needs of patients above own convenience chave with honesty and probity et with sensitivity in a non-confrontational manner oring as a positive contribution to promote personal development a professional regulation and professional development | CbD, mini-CEX, MSF CbD, mini-CEX, MSF CbD, mini-CEX, MSF | 1<br>1<br>1<br>1,2,4 |
| · ·   | right for equity of access to healthcare  | CbD, mini-CEX,   | 1                    |
| Demonstrates<br>team  | s reliability and accessibility throughout the healthcare   | CbD, mini-CEX,<br>MSF                                    | 1                    |
| Level Descrip   | tors  |  |                      |
| Intermediate  | Responds to criticism positively and seeks to understand its origins and works to improve Praises staff when they have done well and where there are failings in delivery of care provides constructive feedback  Comprehends when other staff are under stress and not performing as expected and provides appropriate support for them  Takes action necessary to ensure that patient safety is not compromised   |  |                      |
|   | Engenders trust so that staff feel confident about sharing to point out deficiencies in care at an early stage  | ·  | eel able             |
| Advanced Helps patients who show anger or aggression with staff or with the works with them to find an approach to manage the difficulties bei patient and the healthcare team  |   |  |                      |

#### 1.2 Time management and decision making

To prioritise and organise clinical and clerical duties to optimise patient care and makes appropriate decisions to optimise the effectiveness of the clinical team.

| Knowledge   |   | Assessment<br>Methods | GMP |
|---|---|-----------------------|-----|
| Illustrates the importance  | need to prioritise work according to urgency and  | CbD                   | 1   |
|   | Illustrates the roles, competences and capabilities of other professionals and support workers  |                       | 1   |
| Outlines tech   | niques for improving time management  | CbD                   | 1   |
|   | the importance of prompt investigation, diagnosis and atient management   | CbD, mini-CEX         | 1,2 |
| Skills  |   |                       |     |
| Maintains foc<br>pressures  | us on individual patient needs whilst balancing competing   | CbD                   | 1   |
| Organises an  | d manages workload effectively and flexibly.  | CbD, mini- CEX        | 1   |
| Makes approp  | oriate use of other professionals and support workers   | CbD, mini-CEX         | 1,3 |
| Behaviours  |   |                       |     |
| Works flexibly  | and deals with tasks in an effective and efficient fashion  | CbD, MSF              | 3   |
| Recognises w rectify the situ   | then you or others are falling behind and take steps to ation   | CbD, MSF              | 3   |
| Communicate   | Communicates changes in priority to others  |                       | 1   |
| Remains caln timely, rational   | n in stressful or high pressure situations and adopt a<br>Il approach   | MSF                   | 1   |
| Appropriately consultation  | recognises and handles uncertainty within the   | mini-CEX, MSF         | 1   |
| Level Descri  | otors   |                       |     |
| Completes work in a timely fashion Organises own work efficiently and supervises work of others Intermediate Recognises the most important tasks and responds appropriately Anticipates when priorities should be changed Starting to lead and direct the clinical team in effective fashion Supports others who are falling behind Requires minimal organisational supervision |   |                       |     |
| Advanced  | Automatically prioritises, reprioritises and manages workload efficiently Takes responsibility for organising the clinical team  Advanced Manages, supervises or guides the work of more than one team, e.g. out patient and ward teams  Provides calm leadership in stressful situations |                       |     |

#### 1.3 Decision making and clinical reasoning

To develop the ability to formulate a diagnostic and therapeutic plan for a patient according to the clinical information available

To develop the ability to prioritise the diagnostic and therapeutic plan

To be able to communicate a diagnostic and therapeutic plan appropriately

| Knowledge   |  | Assessment<br>Methods    | GMP        |
|---|--|--------------------------|------------|
| Recognises th<br>presentation   | e psychological component of disease and illness   | CbD, mini-CEX            | 1          |
| Recognises ho   | ow to use expert advice, clinical guidelines and   | CbD, mini-CEX            | 1          |
| Recognises ar accessed by p   | nd appropriately responds to sources of information atients  | CbD, mini-CEX            | 1          |
| Skills  |  |                          |            |
|   | n understanding of the psychological and social inical scenarios into decision making through clinical   | CbD, mini-CEX            | 1          |
|   | the need to determine the best value and most effective for the individual patient and for a patient cohort  | CbD, mini-CEX            | 1          |
| patient, carers   | appropriate management plan in conjunction with the and other members of the clinical team and this effectively to the patient and carers where relevant | CbD, mini-CEX            | 1,3,4      |
| Applies the rel individual patie  | evance of an estimated risk of a future event to an ent  | CbD, mini-CEX            | 1,2        |
| Searches and  | comprehends medical literature to guide reasoning  | Audit Assessment,<br>CbD | 1          |
| Behaviours  |  |                          |            |
| Recognises th   | e difficulties in predicting occurrence of future events   | CbD, mini-CEX            | 1          |
| Shows willingr  | ness to facilitate patient choice  | CbD, mini-CEX            | 3          |
| Shows willingr making   | ness to search for evidence to support clinical decision   | CbD, mini-CEX            | 1,4        |
| Level Descrip   | otors  |                          |            |
| Develops a provisional diagnosis and a differential diagnosis on the basis of the clinical evidence |  |                          | e clinical |
| Intermediate  | Institutes an appropriate investigative plan   |                          |            |
|   | Institutes an appropriate therapeutic plan   |                          |            |
|   | Seeks appropriate support from others  |                          |            |
|   | Takes account of the patients wishes and records them  | accurately and succine   | ctly       |

## 1.4 The patient as central focus of care

| To prioritise th   | To prioritise the patient's wishes encompassing their beliefs, concerns expectations and needs  |                                       |       |  |
|--|---|---------------------------------------|-------|--|
| Knowledge  |   | Assessment<br>Methods                 | GMP   |  |
| and recognise  | h needs of particular populations, e.g. ethnic minorities, es the impact of health beliefs, culture and ethnicity on of physical and psychological conditions | CbD                                   | 1     |  |
| Describes sou  | rces of information and support for patients  | MSF<br>Patient Survey                 | 3     |  |
| Skills   |   |                                       |       |  |
|  | te time for patients and carers to express their beliefs and expectations   | mini-CEX                              | 1,3,4 |  |
| Ascertains the   | e desire of the patient for information   | mini-CEX, MSF<br>Patient survey       | 3     |  |
| Tailors the dis requirements   | cussion and written information to the patients'  | mini-CEX, MSF<br>Patient Survey       | 2     |  |
| Supports patie management  | ents and carers where relevant to comply with plans   | mini-CEX, MSF,<br>Patient Survey      | 1,2,3 |  |
| Encourages p about their ca  | atients to voice their preferences and personal choices re  | mini-CEX, Patient<br>Survey           | 3     |  |
| Behaviours   |   |                                       |       |  |
| Responds to o  | questions honestly and seeks advice if unable to answer   | CbD, mini-CEX                         | 3     |  |
| Recognises the advocate  | ne duty of the medical professional to act as patient   | CbD, mini-CEX,<br>MSF, Patient Survey | 3,4   |  |
|  | s with respect and without discrimination, is polite, nd honest, shows respect for dignity and privacy.   | mini-CEX, MSF,<br>Patient Survey      | 3,4   |  |
| Treats patient   | s fairly and as individuals   | mini-CEX, MSF,<br>Patient Survey      | 3,4   |  |
| Encourages p<br>to improve an  | atients to take an interest in their health and take action d maintain it   | mini-CEX, MSF,<br>Patient Survey      | 2,3   |  |
| Level Descrip  | otors   |                                       |       |  |
| Is sensitive to patients' cultural concerns and norms.  Intermediate Explains diagnoses and treatments in ways that enable patients to understand and make decisions about their own health care.              |   |                                       |       |  |
| Advanced Discusses complex questions and uncertainties with patients and enables them to make decisions about difficult aspects of their health, e.g. to opt for no treatment or to make end of life decisions |   |                                       |       |  |

## 1.5 Patient safety

| To prioritise patient safety throughout all clinical practice.   |   |                       |     |
|--|---|-----------------------|-----|
| Knowledge  |   | Assessment<br>Methods | GMP |
| Outlines the co  | onditions required to maintain a safe working   | CbD                   | 1   |
| Describes the cytotoxic drug   | toxicities of systemic therapies and safe handing of s  | First FRCR,<br>CbD    | 1   |
| Describes the frameworks ar  | principles of radiation protection, including statutory nd local rules                          | First FRCR            | 1   |
| Skills   |   |                       |     |
|  | lleagues in the healthcare team to ensure that patient sed in a way that ensures patient safety | CbD                   | 1   |
| Recognises ar response to the  | nd responds to a patient's deterioration or lack of erapy                                       | CbD, mini-CEX,<br>MSF | 1,2 |
| Improves patie associated wit  | ents' and colleagues understanding of the risks<br>h treatment                                  | CbD, mini-CEX         | 1,3 |
| Ensures that p   | procedures for safe practice are followed   | CbD, mini-CEX         | 1   |
| Behaviours   |   |                       |     |
| Maintains a hi   | gh level of safety awareness at all times   | CbD, mini-CEX         | 2   |
|  | riate action when concerns are raised about own or that of colleagues                           | CbD, mini-CEX,<br>MSF | 3   |
| Continues to b   | be aware of own limitations and operates within these   | CbD, mini-CEX         | 1   |
| Level descrip  | otors   |                       |     |
| Assesses the risks across the system of care and works with colleagues from different department or sectors to ensure safety across the health care system.  Intermediate Involves the whole clinical team in discussions about patient safety Shows support for junior colleagues who are involved in untoward events.            |   |                       |     |
| Is fastidious about following safety protocols and ensures that junior colleagues do the same. Is able to explain the rationale for protocols.  Advanced  Demonstrates ability to lead an investigation of a serious untoward incident or near miss and synthesise an analysis of the issues and plan for resolution or adaptation |   |                       |     |

## 1.6 Team Working

To develop the ability to work well in a variety of different teams

To develop leadership skills required to lead a team to be more effective and able to deliver better patient care

| Care  |   | Assessment                | OMB        |  |
|---|---|---------------------------|------------|--|
| Knowledge   |   | Methods                   | GMP        |  |
| Describes the team  | roles and responsibilities of members of the healthcare   | CbD                       | 1          |  |
| Outlines factor<br>and methods to   | s adversely affecting a doctor's and team performance o rectify these   | CbD                       | 1          |  |
| Skills  |   |                           |            |  |
| Practises with  | attention to providing good continuity of care  | CbD, mini-CEX             | 1,3,4      |  |
|   | ate attributable patient notes, including appropriate use of cal record systems   | CbD, mini-CEX             | 1,3        |  |
| Delivers detaile  | ed hand over between shifts and areas of care   | CbD, mini-CEX ,<br>MSF    | 1,3        |  |
| Demonstrates  | leadership and management in the following areas:   | CbD, mini-CEX,            | 1,2,3      |  |
| Coord   | nates and leads a team based approach to patient care   | MSF                       |            |  |
|   | ing education and training for junior colleagues and other ers of the healthcare team   |                           |            |  |
|   | g with deteriorating performance of colleague (e.g. fatigue)  |                           |            |  |
| <ul> <li>Delive</li> </ul>  | ring high quality care  |                           |            |  |
| Leads and par   | ticipates in multi disciplinary team meetings   | CbD, mini-CEX             | 3          |  |
| Delegates app experienced co  | ropriately whilst providing appropriate supervision to less olleagues   | CbD, MSF                  | 3          |  |
| Behaviours  |   |                           |            |  |
|   | n open environment to foster and explores concerns and the functioning and safety of team working                                   | CbD, MSF                  | 3          |  |
| Recognises lin within these   | Recognises limits of own professional competence and only practise CbD, MSF 3 within these  |                           |            |  |
| Demonstrates  | assertiveness when appropriate  | CbD, MSF                  | 3          |  |
| Recognises ar   | d respects the request for a second opinion   | CbD, MSF                  | 3          |  |
| Recognises the  | e importance of induction for new members of a team   | CbD, MSF                  | 3          |  |
|   | e importance of prompt and accurate information sharing disciplinary and Primary Care teams following hospital                      | CbD, mini-CEX ,<br>MSF    | 3          |  |
| Level descrip   | tors  |                           |            |  |
|   | Develops the leadership skills necessary to lead teams s and able to deliver better safer care                                      | o that they are more e    | ffective   |  |
| Intermediate  | Comprehends need for optimal team dynamics and prom   | notes conflict resolution | า          |  |
|   | Demonstrates ability to convey to patients after a handover of care that although there is a different team, the care is continuous |                           |            |  |
| Leads multi-disciplinary team meetings allowir  |   | s to be heard and cons    | sidered    |  |
|   | Fosters an atmosphere of collaboration  |                           |            |  |
| Advanced Comprehends situations in which others are better equipped to lead or where delegatistic appropriate |   |                           | lelegation |  |
|   | Ensures that team functioning is maintained at all times  |                           |            |  |
|   | Promotes rapid conflict resolution  |                           |            |  |

## 1.7 Principles of quality and safety improvement

To recognise the desirability of monitoring performance, learning from mistakes and adopting no blame culture in order to ensure high standards of care and optimise patient safety

| Knowledge  | Assessment<br>Methods                                   | GMP         |
|--|---|-------------|
| Describes local and national significant event reporting systems (NCEPOD, IRMER, morbidity and mortality, etc) and how this is dealt with within clinical oncology departments | CbD, mini-CEX   | 1           |
| Outlines local health and safety protocols (fire, radiation protection, etc)   | CbD   | 1           |
| Understands risks associated with radiation, chemotherapy and biological therapies and mechanisms to reduce risk   | CbD, First Part<br>FRCR                                 | 1           |
| Outlines potential Quality Improvement and Service Improvement tools such as Plan Do Study Act (PDSA), capacity and demand measurement, root cause analysis and audit          | CbD   | 1,2         |
| Demonstrates knowledge of sources of further support such as the NHS Institute for Innovation and Improvement and the Institute for Health Improvement                         | CbD   | 1,2         |
| Skills   |   |             |
| Adopts strategies to reduce risk   | CbD   | 1,2         |
| Recognises that governance safeguards high standards of care and facilitates the development of improved clinical services   | CbD   | 1,2         |
| Recognise importance of evidence-based practice in relation to clinical effectiveness  | CbD   | 1           |
| Reflects regularly on own standards of medical practice in accordance with GMC guidance on licensing and revalidation  | CbD   | 1,2,3,<br>4 |
| Behaviours   |   |             |
| Demonstrates a willingness to adhere to departmental protocols   | CbD, MSF  | 3           |
| Develops reflection in order to achieve insight into own professional practice   | CbD, MSF  | 3           |
| Demonstrates personal commitment to improve own performance in the light of feedback and assessment  | CbD   | 2           |
| Demonstrates a willingness to participate in, contribute to, respond positively to outcomes of safety and quality improvement strategies, e.g.                                 | CbD, Audit<br>Assessment/Quality<br>Improvement Project | 1,2,3       |
| <ul> <li>reporting adverse clinical incidents and taking part in the<br/>subsequent investigation in serious incidents</li> </ul>  |   |             |
| <ul> <li>Audit of personal and departmental and directorate<br/>performance</li> </ul>   |   |             |
| <ul> <li>Errors / discrepancy meetings</li> </ul>  |   |             |
| <ul> <li>Critical incident and near miss reporting</li> </ul>  |   |             |
| Unit morbidity and mortality meetings  |   |             |
| Local and national databases   |   |             |
| Quality Improvement Project  | 0.5.405   |             |
| Engages with an open no blame culture  | CbD, MSF  | 3           |
|  |   |             |
|  |   |             |

#### **Level Descriptor**

Intermediate

Engages in quality improvement projects and audit and understands the importance of continuous improvement in quality and safety. Demonstrates personal and service improvement in performance

Designs quality improvement projects including audits and demonstrates the role of medical leadership in effecting change

#### 1.8 Audit

| To be able to undertake a clinical audit and complete an audit cycle.  |   |                            |      |  |
|--|---|----------------------------|------|--|
| Knowledge  |   | Assessment<br>Methods      | GMР  |  |
| Defines the diffe  | erence between audit and research   | Audit assessment tool, CbD | 1    |  |
|  | nature of the audit cycle, including the steps involved in and its role in improving patient care and services  | Audit assessment tool      | 1    |  |
| Identifies appropriate data collection, statistical and analytical methods for use in auditing practice  |   | Audit assessment tool      | 1    |  |
| Discusses char resistance to ch  | nge management and the importance of reducing nange   | Audit assessment tool, CbD | 1    |  |
|  | vorking and use of national and local databases for er registries, cancer minimum dataset, cancer waiting   | Audit Assessment tool, CbD | 1    |  |
| Skills   |   |                            |      |  |
| Designs, impler  | ments and completes audit cycles, including:  | Audit assessment           | 1,2  |  |
| <ul> <li>Identify</li> </ul>   | ing an appropriate subject for audit  | tool                       |      |  |
| <ul> <li>Identify</li> </ul>   | ing suitable guidelines to audit against  |                            |      |  |
| <ul> <li>Design</li> </ul>   | ing a form for collection of relevant data  |                            |      |  |
| guidelir   | eting the data extracted and comparing this with the nes and reaching conclusions using appropriate cal and analysis methods  |                            |      |  |
| Developing an action plan  |   |                            |      |  |
| Presenting the data, conclusions and possible action plan to an audit meeting  |   |                            |      |  |
| <ul> <li>Identify</li> </ul>   | ing the change in outcomes required   |                            |      |  |
| <ul><li>Identify<br/>outcom</li></ul>  | ring the change in processes required to achieve those nes  |                            |      |  |
| <ul> <li>Negotia<br/>change</li> </ul>   | ating with the individuals who can deliver those  |                            |      |  |
| Contributes to I   | ocal and national audit projects appropriately, e.g.  | Audit assessment tool, CbD | 1,2  |  |
| Supports audit   | within the MDT  | Audit assessment tool, CbD | 1,2  |  |
| Behaviours   |   |                            |      |  |
| Recognise the setting and qua  | need for audit in clinical practice to promote standard lity assurance  | Audit Assessment tool, CbD | 1, 2 |  |
| Shows willingne  | ess to support changes identified as necessary by   | Audit Assessment tool, CbD | 1,2  |  |
| Level Descriptors  |   |                            |      |  |
| Organises or leads a departmental audit  Compares the results of an audit with criteria and standards to reach conclusions  Uses the findings of an audit to develop and implement change  Understands the links between audit and quality improvement |   |                            | ons  |  |
| Advanced   | Leads a complete clinical audit cycle including development of conclusions, the changes needed for improvement, implementation of findings and re-audit to assess the |                            |      |  |

## 1.9 Complaints and medical error

To recognise the causes of error and to learn from them

To realise the importance of honesty and effective apology

To take a leadership role in the handling of complaints

| Knowledge   |   | Assessment<br>Methods | GMP   |
|---|---|-----------------------|-------|
| Describes the   | local complaints procedure  | CbD, MSF              | 1     |
|   | actors likely to lead to complaints (poor communication, inical errors, adverse clinical outcomes etc)              | CbD, MSF              | 1     |
| Outlines the p  | rinciples of an effective apology   | CbD, MSF              | 1     |
|   | ces of help and support for patients and self when a nade about self or a colleague                                 | CbD, MSF              | 1     |
| Skills  |   |                       |       |
| Contributes to<br>learned from  | processes whereby complaints are reviewed and   | CbD, MSF              | 1     |
|   | then something has gone wrong and identifies aff to communicate with  | CbD, MSF              | 1     |
|   | opropriate apology and explanation (either of error or for estigation of potential error and reporting of the same) | CbD, MSF              | 1,3,4 |
| Distinguishes organisational  | between system and individual errors (personal and  | CbD, MSF              | 1     |
| Shows an abi  | lity to learn from previous error   | CbD, MSF              | 1     |
| Behaviours  |   |                       |       |
| Adopts behav  | iour likely to prevent causes for complaints  | CbD, mini-CEX,<br>MSF | 1, 3  |
| Deals appropi   | riately with concerned or dissatisfied patients or relatives  | CbD, mini-CEX,<br>MSF | 1,3   |
| Acts with hone  | esty and sensitivity in a non-confrontational manner  | CbD, mini-CEX,<br>MSF | 1,3   |
|   | ne impact of complaints and medical error on staff, the National Health Service                                     | CbD, MSF              | 1,3   |
| Contributes to errors   | a fair and transparent culture around complaints and  | CbD, MSF              | 1     |
| Recognises tha complaint  | ne rights of patients, family members and carers to make  | CbD, MSF              | 1,4   |
| Recognises the  | ne impact of a complaint upon self and seeks appropriate port   | CbD, MSF              | 1,2,4 |
| Level Descriptors   |   |                       |       |
| Intermediate  | Manages conflict without confrontation  |                       |       |
| Advanced Comprehends and responds to the difference between system failure and individual error Comprehends and manages the effects of any complaint within members of the team Takes active role in responding to complaints and provides timely accurate written response when required |   |                       |       |

#### 1.10 Communication with colleagues and cooperation

To recognise and accept the responsibilities and role of the doctor in relation to other healthcare professionals

To communicate succinctly and effectively with other professionals as appropriate.

| Knowledge                    |   | Assessment<br>Methods                 | GMP       |
|------------------------------|---|---------------------------------------|-----------|
|                              | s an understanding of the section in "Good Medical<br>Vorking with Colleagues, in particular:   | CbD, MSF                              | 1         |
|                              | ne roles played by all members of a multi-disciplinary am   |                                       |           |
|                              | e principles of effective inter-professional collaboration to timise patient care   |                                       |           |
| Describes the communicate    | principles of confidentiality that provide boundaries to  | CbD                                   | 1         |
| Outlines techi<br>colleagues | niques to manage anger and aggression in self and   | CbD                                   | 1         |
|                              | ponsibility of the doctor in the management of physical ill health in self and colleagues.  | CbD                                   | 1         |
| Skills                       |   |                                       |           |
|                              | es accurately, clearly, promptly and comprehensively with agues in a timely manner  | CbD, mini-CEX                         | 1,3       |
|                              | edures for seeking patient consent for disclosure of and situations where consent while desirable is not  | CbD, mini-CEX                         | 1,3       |
|                              | avioural management skills with colleagues to prevent onflict and enhance collaboration   | CbD, mini-CEX,<br>MSF                 | 1,3       |
| Behaviours                   |   |                                       |           |
| including ado                | ness of the importance of multi-disciplinary teamwork, otion of a leadership role when appropriate but also here others are better equipped to lead | CbD, DORPS,<br>DOST, mini-CEX,<br>MSF | 3         |
|                              | portive and respectful environment where there is open ent communication between all team members   | CbD, mini-CEX,<br>MSF                 | 1,3       |
|                              | opriate confidentiality is maintained during on with any member of the team   | CbD, mini-CEX,<br>MSF                 | 1,3       |
| Recognises the               | ne need for a healthy work/life balance for the whole   | CbD, mini-CEX,<br>MSF                 | 1,3       |
|                              | ional duties in situations of unavoidable and absence of colleagues ensuring that the best interests of e paramount                                 | CbD, MSF                              | 1         |
| Level Descri                 | ptors   |                                       |           |
| Intermediate                 | Fully comprehends the role of and communicates approp team members (individual and corporate)   | riately with all relevant             | potential |
| Advanced                     | Takes a leadership role as appropriate, fully respecting the viewpoints of all team members   | ne skills, responsibilitie            | s and     |

# 1.11 Medical ethics and confidentiality

To know, understand and apply appropriately the principles, guidance and laws regarding medical ethics and confidentiality

| Knowledge   | Assessment<br>Methods                 | GMP    |
|---|---------------------------------------|--------|
| Outlines and follows the guidance given by the GMC on confidentiality   | CbD, mini-CEX                         | 1      |
| Defines the principles of Information Governance  | CbD, mini-CEX                         | 1      |
| Skills  |                                       |        |
| Uses and shares information with the highest regard for confidentiality, and encourages such behaviour in other n of the team                           | CbD, mini-CEX, nembers MSF            | 1,2,3  |
| Recognise the problems posed by disclosure in the public without patient's consent  | c interest, CbD, mini-CEX,<br>MSF     | 1,4    |
| Uses and promotes strategies to ensure confidentiality is maintained e.g. anonymisation   | CbD                                   | 1      |
| Counsels patients on the need for information distribution members of the immediate healthcare team   | within CbD, MSF                       | 1, 3   |
| Counsels patients, family, carers and advocates tactfully effectively when making decisions about resuscitation stawithholding or withdrawing treatment |                                       | 1,3    |
| Behaviours  |                                       |        |
| Encourages informed ethical reflection in others  | CbD, MSF                              | 1      |
| Shows willingness to seek advice of peers, legal bodies a GMC where there are ethical dilemmas regarding confide and information sharing                |                                       | 1      |
| Respects patients' requests for information not to be sharunless this puts the patient, or others, at risk of harm                                      | red, CbD, mini-CEX,<br>Patient Survey | 1,4    |
| Shows willingness to share information with patients about care, unless they have expressed a wish not to receive suinformation                         |                                       | 1,3    |
| Level descriptor  |                                       |        |
| Considers the need for ethical approval value anything other than the individual's care.  Differentiates between confidentiality and                    |                                       | ed for |

## 1.12 Medical ethics and conflict of duty

To know, understand and apply appropriately the principles and guidance regarding conflicts between different ethical duties

| Knowledge  | Assessment<br>Methods | GMP   |
|--|-----------------------|-------|
| Discusses the conflict between ethical duties both to the individual and between the individual patient and broader notions of justice | CBD, Final FRCR       | 1,3,4 |
| Skills   |                       |       |
| Recognises the complexity of decision making where conflicting duties are at stake and justifies a decision on ethical grounds         | CbD, Final FRCR       | 1,4   |
| Explains to patients and their relatives concerns about treatments that are not normally funded  | CbD, Final FRCR       | 3,4   |
| Recognise the factors influencing ethical decision making, including religion, personal and moral beliefs, cultural practices          | CbD, mini-CEX, MSF    | 1,4   |
| Behaviours   |                       |       |
| Shows willingness to seek the opinion of others when making decisions about ethical issues   | CbD, mini-CEX, MSF    | 1,3   |
| Respects opinions of others, including patients, when making decisions about ethical issues  |                       | 3,4   |
| Level descriptor   |                       |       |
| Intermediate Balances conflicting issues to deliver optimal patient car  | re                    |       |

## 1.13 Medical ethics and autonomy and capacity

To know, understand and apply appropriately the principles and guidance regarding the concepts of autonomy and capacity.

| Knowledge  | Assessment<br>Methods       | GMP   |  |
|--|-----------------------------|-------|--|
| Discusses the value and limitations of promotion of autonomy in medicine.  | CbD, Final FRCR             | 1,4   |  |
| Describes the components necessary for informed consent  | CbD, Final FRCR             | 1,3.4 |  |
| Describes the tests for Assessing Capacity   | CbD, Final FRCR             | 1,3,4 |  |
| Accepts the need to respect competent refusal  | CbD, Final FRCR             | 1,3,4 |  |
| Discusses the principles and implications of the Mental Capacity Act, advanced refusals, enduring power of attorney, independent mental capacity advocates | CbD, mini-CEX<br>Final FRCR | 1     |  |
| Skills   |                             |       |  |
| Communicates honestly with patients and their relatives about their disease, benefits and side-effects of treatment and their prognosis                    | CbD, Final FRCR             | 3,4   |  |
| Negotiates with relatives to avoid collusion with them to deny the patient information about their illness   | CbD, Final FRCR             | 3,4   |  |
| Assesses capacity and understands the legal and moral implications of its presence and absence.  | CbD, Final FRCR             | 3,4   |  |
| Behaviours   |                             |       |  |
| Treats patients with respect and without discrimination, is polite, considerate and honest, and shows respect for dignity and privacy.                     | CbD, mini-CEX,<br>MSF       | 3,4   |  |
| Treats patients fairly and as individuals  | CbD, mini-CEX,<br>MSF       | 3,4   |  |
| Level descriptor   |                             |       |  |
| Intermediate Shows ability to support decision making on behalf of those not competent to make decisions about their own care                              |                             |       |  |

#### 1.14 Medical ethics and end of life issues

To understand the ethical and legal issues at the end of life and the concepts of acts, omissions and double effect.

|   | Accepament              |      |
|---|-------------------------|------|
| Knowledge   | Assessment<br>Methods   | GMP  |
| Defines the standards of practice defined by the GMC when deciding to withhold or withdraw life-prolonging treatment  | CbD, mini-CEX           | 1    |
| Appreciates that both acts and omissions carry moral and legal culpability but that whilst allowing patients to die may be defensible, killing them is not. | CbD, Final FRCR         | 1    |
| Accepts that omissions are not legitimate where there is a clear duty to act  | CbD, Final FRCR         | 1    |
| Defines the doctrine of double effect   | CBD, Final FRCR         | 1    |
| Discusses the current guidance on DNAR orders and controversies about these   | CBD, Final FRCR         | 1    |
| Discusses the arguments for and against euthanasia and describes the legal position   | CBD, Final FRCR         | 1    |
| Identifies sources of advice for complex ethical/legal issues   | CBD, Final FRCR         | 1    |
| Skills  |                         |      |
| Applies clear and logical thinking around legal and ethical issues at the end of life   | CBD, Final FRCR         | 1    |
| Documents the issues and views that have been considered, the decisions reached and the reasoning behind those decisions in complex end of life decisions.  | CBD, Final FRCR         | 1,3  |
| Seeks, listens to and values other people's opinions in complex end of life decisions   | CBD, Final FRCR         | 1,3  |
| Behaviours  |                         |      |
| Show willingness to seek the opinion of others when making decisions about resuscitation status, and withholding or withdrawing treatment                   | CbD, mini-CEX, MSF      | 1, 3 |
| Values consensus in complex end-of-life decision making   | CBD, Final FRCR         | 1,3  |
| Level descriptor  |                         |      |
| Intermediate Supports the decision making around end of life issues, competent to make decisions about their own care.                                      | including those who are | not  |

#### 1.15 Valid consent

| To obtain valid consent from the patient  |   |       |
|---|---|-------|
| Knowledge   | Assessment<br>Methods                   | GMP   |
| Outlines the GMC guidance on consent  | CbD, DOST, MSF                          | 1     |
| Skills  |   |       |
| Gives the patient and his/her carers the information and time required to make an informed decision                     | CbD, DOST, mini-<br>CEX, Patient Survey | 1,3   |
| Provides a balanced honest view of treatment options  | CbD, DOST, mini-<br>CEX, Patient Survey | 1,3,4 |
| Behaviours  |   |       |
| Respects the patient's rights to autonomy   | CbD, DOST, mini-<br>CEX, Patient Survey | 1,3,4 |
| Shows willingness to seek advice or offer the patient a second opinion where appropriate                                | CbD, mini-CEX, MSF                      | 1,3,4 |
| Only obtains consent for procedures which they are not competent to perform, in accordance with GMC/regulatory guidance | CbD, mini-CEX                           | 1, 3  |
| Level Descriptor  |   |       |
| Intermediate Supports patients in decision making and obtains valid competent to make decisions about their own care    | consent, including those                | not   |

#### 1.16 Legal framework for practice

To understand the legal framework within which healthcare is provided in the UK and/or devolved administrations in order to ensure that personal clinical practice is always provided in line with this legal framework

|  | Assessment            |      |
|--|-----------------------|------|
| Knowledge  | Assessment<br>Methods | GMP  |
| Illustrates that all decisions and actions must be in the best interests of the patient  | CbD, mini-CEX         | 1    |
| Describes the legislative framework within which healthcare is provided in the UK and/or devolved administrations, including:  | CbD, mini-CEX         | 1, 2 |
| <ul> <li>death certification and the role of the Coroner/Procurator<br/>Fiscal</li> </ul>  |                       |      |
| child protection legislation   |                       |      |
| <ul> <li>mental health legislation (including powers to detain a patient<br/>and giving emergency treatment against a patient's will under<br/>common law);</li> </ul>               |                       |      |
| <ul> <li>advanced directives and living Wills</li> </ul>   |                       |      |
| <ul> <li>withdrawing and withholding treatment</li> </ul>  |                       |      |
| <ul> <li>decisions regarding resuscitation of patients</li> </ul>  |                       |      |
| medical risk and driving   |                       |      |
| Data Protection and Freedom of Information Acts  |                       |      |
| IRMER  |                       |      |
| Outlines sources of medical legal information  | CbD, mini-CEX         | 1    |
| Describes disciplinary processes in relation to medical malpractice  | CbD, mini-CEX,<br>MSF | 1    |
| Outlines the role the medical practitioner in relation to personal health and substance misuse, including understanding the procedure to be followed when such abuse is suspected.   | CbD, mini-CEX,<br>MSF | 1    |
| Skills   |                       |      |
| Cooperates with other agencies with regard to legal requirements   | CbD, mini-CEX         | 1, 3 |
| Prepares appropriate medical legal statements for submission to the Coroner's Court, Procurator Fiscal and other legal proceedings and is prepared to present such material in court | CbD, MSF              | 1    |
| Practices and promotes accurate documentation within clinical practice   | CbD, mini-CEX         | 1, 3 |
| Behaviour  |                       |      |
| Show willingness to seek advice from the employer, appropriate legal bodies (including defence societies), and the GMC on medico-legal matters                                       | CbD, mini-CEX,<br>MSF | 1    |
| Incorporates legal principles into day to day practice   | CbD, mini-CEX         | 1    |
| Demonstrates that all decisions and actions must be in the best interests of the patient   | CbD, mini-CEX,<br>MSF | 1, 3 |

# Actively promotes discussion on medical legal aspects of cases within the clinical environment. Intermediate Participates in decision making with regard to resuscitation decisions and around decisions related to driving discussing the issues openly but sensitively with patients and relatives Works with external strategy bodies around cases that should be reported to them, collaborating with them on complex cases providing full medical legal statements as required and present material in Court where necessary Leads the clinical team in ensuring that medico- legal factors are considered openly and consistently wherever appropriate in the care and best interests of the patient, ensuring that patients and relatives are involved openly in all such decisions.

#### 1.17 Ethical research

| To ensure that research is undertaken using relevant ethical guidelines   |                       |     |
|---|-----------------------|-----|
| Knowledge   | Assessment<br>Methods | GMP |
| Outlines the GMC guidance on good practice in research  | CbD                   | 1   |
| Describes the components of GCP   | CbD                   | 1   |
| Describes the background behind ethical codes for scientific research (Nuremberg, Helsinki etc)   | CbD                   | 1   |
| Defines the difference between audit and research   | CbD, Audit assessment | 1   |
| Demonstrates a knowledge of research principles   | CbD, First FRCR       | 1   |
| Outlines the principles of formulating a research question and designing a project  | CbD, mini-CEX         | 1   |
| Comprehends principal qualitative, quantitative, bio-statistical and epidemiological research methods   | CbD, First FRCR       | 1   |
| Describes the mechanism of ethical approval for research studies  | CbD                   |     |
| Outlines sources of research funding  | CbD                   | 1   |
| Discusses the ethical rationale and values the importance of scientific research  | CbD                   | 1   |
| Discusses the potential for conflicting ethical values between patient care and scientific research and how these are resolved  | CbD                   | 1   |
| Skills  |                       |     |
| Uses critical appraisal skills and applies these when reading literature  | CbD, First FCR        | 1   |
| Demonstrates the ability to write a scientific paper  | CbD                   | 1   |
| Applies for appropriate ethical research approval   | CbD                   | 1   |
| Understands the difference between population-based assessment  | CbD, First FCR        | 1   |
| and unit-based studies and be able to evaluate outcomes for epidemiological work  |                       |     |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:   | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value   | СЬД                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  • Fair subject selection  | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  • Fair subject selection  • Favourable risk/ benefit ratio  | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  • Fair subject selection  | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  • Fair subject selection  • Favourable risk/ benefit ratio  • Independent review  | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  • Fair subject selection  • Favourable risk/ benefit ratio  • Independent review  • Informed consent  | CbD                   | 1   |
| epidemiological work  Assesses research against the criteria to determine whether it is ethical, including:  • Social/ Scientific value  • Scientific validity  • Fair subject selection  • Favourable risk/ benefit ratio  • Independent review  • Informed consent  • Respect for potential and enrolled subjects | CbD                   | 1   |

| Level Descriptors |   |  |  |
|-------------------|---|--|--|
| Intermediate      | Demonstrates critical appraisal skills and demonstrates ability to critically appraise a published paper  |  |  |
|                   | Demonstrates knowledge of research organisation and funding sources   |  |  |
| Advanced          | Demonstrates ability to write a scientific paper  Demonstrates ability to apply for appropriate ethical research approval if appropriate  Provides leadership in research when relevant  Promotes research activity |  |  |

## 1.18 Evidence and guidelines

To make the optimal use of current best evidence in making decisions about the care of patients To develop the ability to construct evidence based guidelines and protocols in relation to medical practise

| Knowledge   |  | Assessment<br>Methods   | GMР   |  |
|---|--|-------------------------|-------|--|
| Outlines the pr   | inciples of critical appraisal   | CbD, First FRCR         | 1     |  |
|   | advantages and disadvantages of different study (quantitative and qualitative) for different types of          | CbD, First FRCR         | 1     |  |
| Outlines levels   | of evidence and quality of evidence  | CbD, First FRCR         | 1     |  |
| Demonstrates  | how to apply statistics in scientific medical practice   | CbD, First FRCR         | 1     |  |
|   | between the use and differences between the basic sk and uncertainty   | CbD, First FRCR         | 1     |  |
|   | role and limitations of evidence in the development of<br>les and protocols                                    | CbD, First FRCR         | 1     |  |
| Describes how SIGN)   | guidelines and protocols are developed (e.g. NICE and  | CbD                     | 1     |  |
| Skills  |  |                         |       |  |
|   | nedical literature including use of PubMed, Medline, ews and the internet                                      | CbD                     | 1     |  |
| Appraises retri   | eved evidence to address a clinical question   | CbD                     | 1     |  |
| Applies conclu  | sions from critical appraisal into patient care  | CbD                     | 1     |  |
| Contributes to the construction, review and updating of local (and CbD 1 national) guidelines of good practice                |  |                         | 1     |  |
| Behaviours  |  |                         |       |  |
| Aims for best clinical practice (clinical effectiveness) at all times, as CbD, mini-CEX 1 informed by evidence based medicine |  |                         |       |  |
| Recognises kn   | Recognises knowledge gaps and seeks to address them CbD, MSF 1   |                         |       |  |
|   | ate with national reviews, key new relevant research, of practice (e.g. NICE and SIGN)                         | CbD                     | 1     |  |
| Recognises the  | e need to practise outside clinical guidelines at times  | CbD, mini-CEX           | 1     |  |
| Communicates information about risk and risk-benefit trade-offs, in CbD, mini-CEX ways appropriate for the individual patient |  | CbD, mini-CEX           | 1,3,4 |  |
| Encourages dis<br>practice  | Encourages discussion amongst colleagues on evidence-based CbD, mini-CEX, 1 practice MSF                       |                         |       |  |
| Level Descriptors   |  |                         |       |  |
| Undertakes a literature review in relation to a clinical problem or topic and present the same                                |  |                         |       |  |
| intermediate  | Intermediate Explains the evidence base of clinical care to patients and to other members of the clinical team |                         |       |  |
| Advenced  | Produces a review on a clinical topic, having reviewed a literature  | and appraised the relev | ant   |  |
| Advanced  | Collaborates in a systematic review of the medical literature  |                         |       |  |
| Contributes to the development of local or national clinical guidelines and protocols   |  |                         | cols  |  |

# 1.19 Continuing professional development

| To be able to take responsibility for personal learning and continuing professional development. |                       |     |  |  |
|--|-----------------------|-----|--|--|
| Knowledge  | Assessment<br>Methods | GMP |  |  |
| Describes how adults learn and how principles relate to personal development                     | CbD                   | 1   |  |  |
| Outlines the structure of an effective appraisal interview                                       | CbD                   | 1   |  |  |
| Differentiates between appraisal and assessment and performance review                           | CbD                   | 1   |  |  |
| Discusses who to refer to if problems are identified during training                             | CbD                   | 1   |  |  |
| Skills   |                       |     |  |  |
| Develops personal development plan and portfolio to ensure continuing personal development       | MSF                   | 1   |  |  |
| Uses workplace-based assessments and appraisals as an opportunity for personal development       | CbD, MSF              | 1   |  |  |
| Uses different learning methods effectively to develop personal skills and knowledge             | MSF                   | 1   |  |  |
| Behaviours   |                       |     |  |  |
| Shows willingness to seek and learn from feedback  | MSF                   | 1,3 |  |  |
| Show willingness to undertake workplace-based assessments  | CbD, MSF              | 1   |  |  |
| Encourages discussions colleagues with colleagues to share knowledge and understanding           | CbD, MSF              | 1,3 |  |  |
| Maintains honesty and objectivity during appraisal and assessment                                | CbD, MSF              | 1   |  |  |
| Recognises the importance of personal development in guiding good professional behaviour         | CbD, MSF              | 1   |  |  |
| Demonstrates a willingness to advance own educational capability through continuous learning     | CbD, MSF              | 1   |  |  |
| Level Descriptors  |                       |     |  |  |
| Intermediate Takes responsibility for learning and personal development                          | nent planning         |     |  |  |

# 1.20 Teaching

| To be able to deliver teaching in a variety settings  |                                      |     |
|---|--------------------------------------|-----|
| Knowledge   | Assessment<br>Methods                | GMP |
| Describes how adults learning principles relate to medical education  | CbD, Teaching observation            | 1   |
| Demonstrates knowledge of relevant developments and challenges in medical education                                   | CbD, Teaching observation            | 1   |
| Describes the assessment system and its place in relation to formative and summative assessment                       | CbD, Teaching observation            | 1   |
| Demonstrates an understanding of the place of workplace based assessments   | CbD, Teaching observation            | 1   |
| Skills  |                                      |     |
| Identifies learning needs of others and self and varies teaching format appropriately                                 | CbD, MSF,<br>Teaching<br>observation | 1   |
| Structures and delivers clinical teaching sessions effectively, including:  | MSF, Teaching observation            | 1   |
| Small group teaching  |                                      |     |
| Presentations   |                                      |     |
| Lectures  Pad side to achieve accessors   |                                      |     |
| <ul><li>Bed side teaching sessions</li><li>Appropriate design and use of audiovisual aids</li></ul>                   |                                      |     |
| Appropriate design and use of additivisual aids     Allowing active audience participation                            |                                      |     |
| Communicates feedback effectively and appropriately   | MSF                                  | 1   |
| Undertakes supervision, workplace-based assessments, appraisal, mentoring as appropriate                              | MSF                                  | 1   |
| Recognises the trainee in difficulty and take appropriate action, including where relevant referral to other services | CbD, MSF                             | 1   |
| Leads departmental teaching programmes including journal clubs  | CbD, Teaching observation            | 1   |
| Participates in strategies aimed at improving patient education, e.g. talking at support group meetings               | CbD, MSF                             | 1   |

| Behaviours  |  |                                      |     |
|---|--|--------------------------------------|-----|
| Maintains dign<br>educational du  | ity and safety of patients at all times when discharging ties  | CbD, MSF,<br>Teaching<br>observation | 1,4 |
| Shows willingr  | ness to seek and learn from feedback   | MSF, Teaching observation            | 1,3 |
|   | willingness to teach trainees and other health and in a variety of settings                                  | CbD, MSF,<br>Teaching<br>observation | 1   |
|   | consideration for learners, including their emotional, sychological well being with their development needs. | CbD, MSF,<br>Teaching<br>observation | 1   |
| Acts to ensure professional co  | equality of opportunity for students, trainees, staff and olleagues  | CbD, MSF,<br>Teaching<br>observation | 1   |
| Shows willingrassessments   | ness to undertake assessment of workplace-based  | CbD, MSF                             | 1   |
| Maintains hone  | esty and objectivity during appraisal and assessment   | CbD, MSF                             | 1   |
|   | e importance of personal development in guiding pects of good professional behaviour                         | CbD, MSF                             | 1   |
| Level Descriptors   |  |                                      |     |
| Delivers teaching to different staff groups in a variety of formats  Intermediate Performs workplace-based assessments, giving effective and appropriate feedback  Acts as a mentor for junior colleagues |  |                                      |     |
| Advanced Plans and organises a teaching programme within the oncology department  |  |                                      | t   |

#### 1.21 Management and NHS structure

To understand the structure of the NHS and the management of local healthcare systems in order to be able to participate fully in managing healthcare provision

| Knowledge  | Assessment<br>Methods | GMP |
|--|-----------------------|-----|
| Outlines the guidance given on management and doctors by the GMC   | CbD                   | 1   |
| Understands the local structure of NHS systems in your locality, recognising potential differences between the four countries of the UK  | CbD                   | 1   |
| Evaluates major national reports on cancer care e.g. Cancer Reform Strategy, National Radiotherapy Advisory Group and National Chemotherapy Advisory Group reports   | CbD                   | 1   |
| Evaluates possible future developments in the organisation of cancer services  | CbD                   | 1   |
| Describes the local structure of NHS systems in the locality, including the department's management and committee structure recognising the potential differences between the four countries of the UK     | CbD                   | 1   |
| Describes how cancer services are commissioned for patients  | CbD                   | 1   |
| Understands the consistent debates and changes that occur in the NHS including the political, social, technical, economic, organisational and professional aspects that can impact on provision of service | CbD                   | 1   |
| Describes the principles of:   | CbD, mini-CEX         | 1   |
| Clinical coding  |                       |     |
| European Working Time Regulations including rest provisions  |                       |     |
| NHS finance and budgeting  |                       |     |
| Consultant contract and the contracting process  |                       |     |
| Resource allocation  |                       |     |
| The role of the independent sector as providers of healthcare  |                       |     |
| Patient and public involvement processes and role  |                       |     |
| Recruitment and appointment procedures   |                       |     |
| Skills   |                       |     |
| Participates in managerial meetings  | MSF, CbD              | 1   |
| Works with stakeholders to create and sustain a patient-centred service  | CbD, mini-CEX         | 1   |
| Analyses information and uses it appropriately to promote service developments   | CbD, mini-CEX         | 1   |
| Prioritises use of resources, including allocating beds and making best use of staffing resources, particularly when these are stretched by competing demands  | MSF                   |     |

| Behaviour  |                                  |       |
|--|----------------------------------|-------|
| Recognises the importance of equitable allocation of healthcare resources and of commissioning   | CbD                              | 1,2   |
| Recognises the role of doctors as active participants in healthcare systems  | CbD, mini-CEX                    | 1,2   |
| Responds appropriately to health service objectives and targets and take part in the development of services   | CbD, mini-CEX                    | 1,2   |
| Recognises the role of patients and carers as active participants in healthcare systems and service planning   | CbD, mini-CEX,<br>Patient Survey | 1,2,3 |
| Takes an active role in promoting the best use of healthcare resources   | CbD, mini-CEX,<br>MSF            | 1     |
| Shows willingness to improve leadership and managerial skills (e.g. management courses) and engage in leadership and management of the service (e.g. to be a member of departmental and cancer network committees) | CbD, MSF                         | 1     |
| Level Descriptors  |                                  |       |

| · ·          |   |
|--------------|---|
| Intermediate | Discusses guidance from the relevant health regulatory agencies in relation to cancer care  |
|              | Describes the local structure for health services and how they relate to regional or devolved administration structures                                     |
| Advanced     | Discusses funding allocation processes from central government in outline and how that might impact on the local health organisation                        |
|              | Participates fully in clinical directorate meetings and other appropriate local management structures in planning and delivering healthcare within oncology |
|              | Collaborates with other stake holders in the cancer community to ensure that their needs and views are considered in managing services                      |
|              | Participates as appropriate in staff recruitment processes  |

# 2 Introductory module

#### 2.1 Authorising chemotherapy

To be able to review a patient receiving cytotoxic chemotherapy

To authorise the next cycle of previously-prescribed treatment, enabling treatment to proceed.

| Knowledge  | Assessment<br>Methods | GMP   |
|--|-----------------------|-------|
| Describes safe handling of cytotoxic drugs   | CbD                   | 1,2   |
| Describes the methods of calculating the correct dose of chemotherapy  | CbD                   | 1     |
| Describes the possible side effects of treatment   | CbD                   | 1     |
| Skills   |                       |       |
| Takes a focused history to ensure that patient's condition has not changed since treatment was prescribed                | DOST                  | 1,3   |
| Identifies when the dose should be reduced or the cycle delayed  | CbD, DOST             | 1,2   |
| Behaviour  |                       |       |
| Elicits patient and carers concerns about treatment and ensures that they are addressed appropriately                    | DOST, MSF             | 3,4   |
| Ensures that patient has all relevant written information regarding treatment, especially emergency contact instructions | DOST, MSF             | 2,3,4 |
| Remains open to advice from other health professionals on chemotherapy issues  | DOST, MSF             | 1,3   |
| See sections 1.3, 1.4 and 1.5  | DOST, MSF             | 3,4   |

## 2.2 Prescribing chemotherapy

To be able to prescribe cytotoxic chemotherapy within local guidelines, continuing a planned course of treatment (but not initiate first cycle of treatment).

| Knowledge   | Assessment<br>Methods | GMP   |
|---|-----------------------|-------|
| Describes the common side effects of chemotherapy in common use   | CbD, DOST             | 1,2   |
| Describes the use of supportive measures both pharmacological and non pharmacological to treat toxic effects of chemotherapy                                      | CbD, DOST             | 1,2   |
| Describes methods of assessing tumour response  | CbD, DOST             | 1     |
| Defines the effects of age, body size, organ dysfunction and concurrent illnesses on drug distribution and metabolism of cytotoxic drugs                          | CbD, DOST             | 1,2   |
| Describes interactions between chemotherapy and other commonly prescribed drugs   | CbD, DOST             | 1,2   |
| Skills  |                       |       |
| Takes a focused history and performs a relevant examination to assess tumour response, side effects of treatment, patient's performance status and co-morbidities | DOST                  | 1,2,3 |
| Assesses toxicity of the previous cycle of chemotherapy   | DOST                  | 1,2   |
| Modifies the dose of chemotherapy correctly in response to clinical findings and laboratory parameters  | DOST                  | 1,2   |
| Ensures appropriate arrangements are in place for subsequent patient review   | CbD, DOST             | 1     |
| Uses electronic prescribing system where available to improve patient safety  | DOST                  | 1,2   |
| Behaviour   |                       |       |
| Ensures treatment information is shared promptly and accurately with patient's GP and other specialties involved in supporting the patient                        | CbD, DOST             | 1,3   |
| See sections 2.1, 1.3, 1.4 and 1.5  |                       |       |

#### 2.3 Safety in radiation treatment

| To be aware of issues of patient and personal safety with regard to radiation treatment.       |                       |     |  |
|--|-----------------------|-----|--|
| Knowledge  | Assessment<br>Methods | GMP |  |
| Describes IRMER regulations and the procedures in place in the department to comply with these | CbD                   | 1,2 |  |
| Identifies the requirement for an ARSAC certificate  | CbD                   | 1,2 |  |
| Skills   |                       |     |  |
| See Section 1.5  |                       |     |  |
| Behaviour  |                       |     |  |
| See Section 1.5  |                       |     |  |

## 2.4 Outpatient consultation

To be able to structure an outpatient consultation and to communicate with patients, and carers where appropriate, clearly and in an empathetic manner.

| Knowledge  | Assessment<br>Methods            | GMP   |
|--|----------------------------------|-------|
| Recognises that patients do not present a history in a structured fashion  | mini-CEX                         | 1,3   |
| Recognises that patient's wishes and beliefs and the history should inform examination and investigations                          | mini-CEX                         | 1     |
| Discusses the need for targeted clinical examination   | CbD, mini-CEX                    | 1     |
| Discusses the limitations of physical examination and the need for appropriate investigations to confirm a diagnosis               | CbD, mini-CEX                    | 1     |
| Skills   |                                  |       |
| Assesses and summarises the previous hospital notes  | CbD, mini-CEX                    | 1     |
| Greets patient appropriately and establishes a rapport, overcoming barriers to communication                                       | mini-CEX                         | 1,3   |
| Elicits patient's main concerns  | mini-CEX                         | 1,3,4 |
| Performs focused history and examination   | CbD, mini-CEX                    | 1,3   |
| Determines the level of information the patient wishes to receive  | mini-CEX                         | 1,3,4 |
| Explains the current situation to the patient and if necessary breaks bad news   | mini-CEX                         | 1,3,4 |
| Negotiates agreed outcomes with the patient  | mini-CEX                         | 1,3,4 |
| Organises appropriate investigations, treatment and referrals to other professionals   | CbD, mini-CEX                    | 1,3   |
| Communicates clearly in the notes and in the letter to the referring doctor and GP   | mini-CEX, MSF                    | 3,4   |
| Behaviours   |                                  |       |
| Treats patients with respect and without discrimination, is polite, considerate and honest, shows respect for dignity and privacy. | mini-CEX, MSF,<br>Patient survey | 1,3,4 |
| Treats patients fairly and as individuals  | mini-CEX, MSF                    | 1,3,4 |
| Shows empathy with the patient's situation and offers appropriate emotional support  | mini-CEX, MSF,<br>Patient survey | 3,4   |
| Ensures appropriate personal language and behaviour  | mini-CEX, MSF,<br>Patient survey | 1,3   |
| Shows willingness to provide the patient with a second opinion   | mini-CEX, MSF                    | 1,3   |
| Uses different methods of ethical reasoning to come to a balanced decision where complex and conflicting issues are involved       | CbD, mini-CEX,<br>MSF            | 1,3   |
| Behaves in accordance with Good Medical Practice   | mini-CEX, MSF                    | 3,4   |

## 2.5 Breaking bad news

To be able to skilfully deliver bad news using appropriate strategies according to the needs of the patients.

| Knowledge  | Assessment<br>Methods | GMP   |
|--|-----------------------|-------|
| Describes models of breaking bad news  | CbD, mini-CEX,        | 1,3   |
| Discusses the range of likely reactions to bad news  | CbD, mini-CEX         | 1,3   |
| Discusses the different connotations of bad news depending on the context, individual, social and cultural circumstances | CbD, mini-CEX         | 1     |
| Skills   |                       |       |
| Recognises the impact of bad news on the patient, carers, staff members and self   | CbD, mini-CEX         | 1,3   |
| Structures interview appropriately and ensures that patient has the necessary support during the interview               | CbD, mini-CEX         | 1,3   |
| Responds to verbal and non-verbal cues from patient and carers   | CbD, mini-CEX         | 1,3   |
| Elicits patient's main concerns  | mini-CEX              | 1,3,4 |
| Determines the level of information the patient wishes to receive  | mini-CEX              | 1,3,4 |
| Explains situation to the patient and carers using appropriate language  | CbD, mini-CEX         | 1,3,4 |
| Encourages questioning and ensures patient understands information given   | CbD, mini-CEX         | 1,3   |
| Ensures that appropriate on going support and follow up arrangements are in place  | CbD, mini-CEX,<br>MSF | 1,3,4 |
| Behaviours   |                       |       |
| Respects the different ways that patients react to bad news  | CbD, MSF              | 1     |
| Shows empathy with the patient's situation and offers appropriate emotional support                                      | mini-CEX, MSF         | 3,4   |
| Shows respect for the opinions of other team members regarding a patient's likely and on going response to bad news      | CbD, MSF              | 1,3   |
| Encourages team working to ensure that patients receiving bad news have appropriate support                              | CbD, MSF              | 1,3   |

# 3 Oncology emergencies syllabus

## To be completed by the end of ST3

#### 3.1 Infections

| To be able to diagnose and manage infections, especially in immunocompromised patients.                             |                       |         |
|---|-----------------------|---------|
| Knowledge   | Assessment<br>Methods | GMP     |
| Lists the infections that occur commonly in cancer patients undergoing treatment and describes how to diagnose them | CbD                   | 1,2     |
| Knows the antibiotic, antiviral and antifungal policies of the hospital   | CbD                   | 1,2     |
| Skills  |                       |         |
| Takes a focused history and performs a focused examination  | CbD, mini-CEX         | 1,2,3,4 |
| Requests appropriate investigations and interprets imaging  | CbD                   | 1       |
| Resuscitates patients and prescribes appropriate supportive care and antibiotics                                    | CbD, mini-CEX         | 1,2     |
| Evaluates the importance of prognosis in influencing escalation of treatment  | CbD                   | 1,2     |
| Recognises when escalation of care to HDU/ITU is indicated and appropriate  | CbD                   | 1,2     |
| Discusses treatment with patient and carers   | mini-CEX              | 3,4     |
| Behaviours  |                       |         |
| See Sections 1.2, 1.3, 1.4 1.5 and 1.15   |                       |         |

#### 3.2 Spinal cord compression

| To be able to diagnose and manage spinal cord compression.                               |                       |       |
|--|-----------------------|-------|
| Knowledge  | Assessment<br>Methods | GMP   |
| Describes the symptoms and signs of spinal cord compression                              | CbD,                  | 1,2   |
| Identifies the appropriate radiological investigations                                   | CbD                   | 1,2   |
| Describes the roles of steroids, surgery, radiotherapy and rehabilitation                | CbD                   | 1,2   |
| Skills   |                       |       |
| Assesses the level of spinal cord compression clinically                                 | mini-CEX              | 1     |
| Interprets MRI imaging   | CbD, DORPS            | 1     |
| Discusses options with patient and colleagues and recommends most appropriate management | CbD, mini-CEX         | 1,3,4 |
| Plans radiotherapy treatment under appropriate supervision                               | DORPS                 | 1,2   |
| Plans appropriate supportive care/rehabilitation   | CbD                   | 1,3   |
| Behaviours   |                       |       |
| See Sections 1.2, 1.3, 1.4 and 1.6   |                       |       |

#### 3.3 Superior vena cava obstruction (SVCO)

| To be able to diagnose and manage SVCO.  |                       |       |
|--|-----------------------|-------|
| Knowledge  | Assessment<br>Methods | GMP   |
| Describes the symptoms and signs of SVCO   | CbD                   | 1     |
| Lists the differential diagnosis   | CbD                   | 1     |
| Describes the role of different treatment modalities   | CbD                   | 1     |
| Skills   |                       |       |
| Performs a focussed history and examination and recognises the diagnosis clinically                                | CbD, mini-CEX         | 1,3,4 |
| Interprets imaging   | CbD                   | 1,2   |
| Discusses diagnostic and treatment options with patient and colleagues and recommends the most appropriate pathway | mini-CEX              | 3,4   |
| Plans radiotherapy/chemotherapy treatment as appropriate, under supervision  | DORPS, DOST           | 1,2   |
| Behaviours   |                       |       |
| See Sections 1.3 and 1.4   |                       |       |

#### 3.4 Metabolic disorders

To be able to diagnose and manage metabolic disorders commonly associated with cancer, including hypercalcaemia, hyperuricaemia, tumour lysis syndrome, hypo/hyperglycaemia and hyperbilirubinaemia

| Knowledge  | Assessment<br>Methods | GMP   |
|--|-----------------------|-------|
| Describes the symptoms, signs and laboratory findings of metabolic disorders associated with cancer  | CbD                   | 1     |
| Lists the differential diagnosis of the possible causes  | CbD                   | 1     |
| Describes measures to reduce the risk of occurrence where appropriate                                | CbD                   | 1,2   |
| Skills   |                       |       |
| Determines the blood tests and imaging studies required to establish a diagnosis and interprets them | CbD                   | 1     |
| Determines and institutes clinical management and liaises with other specialities as appropriate     | CbD                   | 1,2,3 |
| Behaviours   |                       |       |
| See Sections 1.3, 1.4 and 1.6  |                       |       |

## 3.5 Organ failure

To be able to manage major organ failure: respiratory/cardiovascular failure, renal failure and hepatic failure.

| Knowledge   | Assessment Methods | GMP   |
|---|--------------------|-------|
| Describes the symptoms, signs, laboratory and imaging findings  | CbD                | 1     |
| Lists the differential diagnosis of the possible causes   | CbD                | 1     |
| Skills  |                    |       |
| Performs a focused history and examination and is able to develop a differential diagnosis clinically | CbD, mini-CEX      | 1,3,4 |
| Determines the blood tests and imaging studies required and interprets them                           | CbD, mini-CEX      | 1     |
| Evaluates the treatment options and how the patient's prognosis influences these                      | CbD, mini-CEX      | 1     |
| Determines and institutes clinical management and liaises with other specialities as appropriate      | CbD, mini-CEX      | 1,2,3 |
| Behaviours  |                    |       |
| See Sections 1.2, 1.3, 1.4, 1.6, 1.9, 1.13 and 1.15   |                    |       |

#### 3.6 Reduced conscious level

| To be able to manage patients with a reduction in their conscious level.                         |                       |       |
|--|-----------------------|-------|
| Knowledge  | Assessment<br>Methods | GMP   |
| Lists the differential diagnosis of the causes of reduced conscious level                        | CbD                   | 1     |
| Describes the legislation around 'loss of capacity' of a patient to make a decision              | CbD                   | 1,2   |
| Skills   |                       |       |
| Performs a focussed clinical examination   | CbD, mini-CEX         | 1,3,4 |
| Determines the blood tests and imaging studies required and interprets them                      | CbD                   | 1,2   |
| Evaluates the treatment options and how the patient's prognosis influences these                 | CbD                   | 1     |
| Determines and institutes clinical management and liaises with other specialities as appropriate | CbD, mini-CEX         | 1,2,3 |
| Behaviours   |                       |       |
| See Sections 1.2, 1.3, 1.4, 1.6, 1.9, 1.10, 1.11, 1.12 and 1.15                                  |                       |       |

## 4 Site-specific learning outcomes

Each cancer site is placed in one of four groups:

#### Group A

The common tumours where the majority of learning outcomes should be achieved by the end of ST4

#### • Group B

A group of tumours where the majority of learning outcomes should be achieved by the end of ST5

#### • Group C

A group of tumours where some learning outcomes should be achieved by the end of ST5 and the majority will be achieved by CCT

#### • Group D

A group of uncommon tumours and specialised techniques where a few learning outcomes should be achieved by ST5 and achieved by mainly CCT

For each group of tumours the stage of training by which the trainee should have achieved the learning outcomes is shown as:

- Core completed by the end of ST4
- Intermediate completed by the end of ST5
- Advanced tumour-site specialisation undertaken post-FRCR and completed CCT

Table showing composition of each group

| Group  | Site/type or treatment technique | Subsite/subtype |
|--|----------------------------------|-----------------|
| Groups A: common<br>subjects where the<br>majority of learning<br>outcomes achieved by<br>the end of ST4 | Breast cancer                    |                 |
|  | Lung cancer                      | Non-small cell  |
|  |                                  | Small cell      |
|  | Lower gastrointestinal cancer    | Caecum          |
|  |                                  | Colon           |
|  |                                  | Rectum          |
|  | Urological cancer                | Prostate        |

| Group   | Site/type or treatment technique | Subsite/subtype   |
|---|----------------------------------|---|
| Group B: where the majority of learning outcomes achieved by the end of ST5 | Thoracic cancer                  | Mesothelioma Thymic tumours Mediastinal germ cell   |
|   | Upper gastrointestinal cancer    | Oesophagus<br>Stomach<br>Pancreas   |
|   | Lower gastrointestinal cancer    | Anal canal and anal margin  |
|   | Head and neck cancer             | Larynx Pharynx Oropharynx Oral cavity Paranasal sinuses Nasopharynx Salivary gland tumours Thyroid Middle ear |
|   | Sarcoma                          | Soft tissue Gastrointestinal stromal tumours  |
|   | Gynaecological cancer            | Cervix Body of Uterus Ovary   |
|   | Urological cancer                | Bladder Kidney Penis Testicular tumours   |
|   | Central nervous system tumours   | Gliomas Meningiomas Vestibular schwannomas Pituitary adenomas   |
|   | Skin cancer                      | Non-melanoma<br>Melanoma  |
|   | Lymphoma/leukaemia/myeloma       | Hodgkin lymphoma<br>Non-Hodgkin lymphoma<br>Plasmacytoma/myeloma  |
|   | Unknown primary cancer           |   |

| Group   | Site/type or treatment technique   | Subsite/subtype  |
|---|--|--|
| Group C: where some learning outcomes achieved by the end of  | Upper gastrointestinal cancer  | Gall bladder and biliary tract Primary liver   |
| ST5   | Head and neck cancer   | Nasal passages Temporal bone tumours   |
|   | Sarcoma  | Primary bone tumours Ewing's sarcoma of bone and soft tissue (adult)   |
|   | Gynaecological cancer  | Fallopian tube Primary peritoneum Vulva and vagina   |
|   | Urological cancer  | Ureter<br>Urethra  |
|   | Central nervous system tumours   | Craniopharyngioma Ependymoma Pineal lesions Primitive neuroectodermal tumours Primary cerebral lymphoma Medulloblastoma Skull base tumours |
|   | Skin cancer  | Cutaneous lymphoma   |
| Group D: a few learning outcomes achieved by the end of ST5 but they will mainly be achieved by CCT | Paediatric and adolescent oncology including specific paediatric malignancies and specific issues arising when treating paediatric patients who have tumours which are found in adults | Central nervous system tumours Wilms' tumour Neuroblastoma Rhabdomyosarcoma Ewing's sarcoma Lymphoma Leukaemia                             |
|   | Brachytherapy clinical experience  | Gynaecological cancer Prostate cancer Head and neck cancer Other   |
|   | Proton and neutron therapy   |  |

### **Underpinning attitudes and behaviours**

The site-specific learning outcomes in this section of the syllabus are underpinned by appropriate attitudes and behaviours which are drawn from Good Medical Practice (GMP). Since many of the learning outcomes for these attitudes and behaviours are already listed in the Common Competencies for Clinical Oncology (Appendix 1, Section 1), they are not repeated here; instead, where appropriate, reference is made to the relevant part of Section 1. In summary, each trainee must:

- 1. Display a willingness to make the care of the patient their first concern
- 2. Appreciate the need to protect and promote the health of patients and the public
- 3. Display a willingness to provide a good standard of practice and care by:
  - Keeping their professional knowledge and skills up to date
  - Recognising and working within the limits of their competence
  - Displaying a willingness to work with colleagues in the ways that best serve patients' interests:
    - o Respecting their skills and contributions and treating them fairly
    - Communicating effectively with them
    - Supporting colleagues who have problems with performance, conduct or health while protecting patients from risk of harm
    - Avoiding malicious or unfounded criticisms of colleagues
    - o Demonstrating effective handover procedures when going off duty
- 4. Demonstrate the need to treat patients as individuals and respect their dignity, by
  - Treating patients politely, considerately and honestly
  - Respecting patients' right to confidentiality
- 5. Display a willingness to work in partnership with patients:
  - Listening to patients and responding to their questions, concerns and preferences and keeping them informed about the progress of their care
  - Sharing with patients, in a way they can understand, the information they want or need to know about their condition, its likely progression, and the treatment options available to them, including associated risks and uncertainties
  - Respecting patients' rights to reach decisions about their treatment and care
  - Supporting patients in caring for themselves to improve and maintaining their health
- 6. Display honesty and openness and act with integrity:
  - Acting without delay if they have good reason to believe that they or a colleague may be putting patients at risk
  - Never discriminating unfairly against patients or colleagues
  - Never abusing the patients' trust in him/her or the public's trust in the profession, by always displaying:
    - Honesty and trustworthiness when writing or signing any documents, reports or CVs
    - Honesty and integrity when undertaking research putting the protection of the participants' interests first
    - Honesty in financial dealings with employers and other organisations or individuals.

# Underpinning scientific knowledge

The scientific knowledge of radiotherapy physics, tumour biology, radiobiology, clinical pharmacology and medical statistics that underpins clinical oncology training is common to all tumour groups. It is therefore essential that trainees acquire this knowledge by the end of core training (ST5). This knowledge is defined in Appendix 2 and is assessed in the First FRCR examination.

### **Tumour Site-Specific Learning Outcomes**

### 4.1 Radiology

| To be able to relate clinical and radiological anatomy to diagnosis and therapy   |                        |     |
|---|------------------------|-----|
| Level   |                        |     |
| Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced   |                        |     |
| Knowledge   | Assessment<br>Methods  | GMP |
| Describes clinical and radiological anatomy                                       | CbD, DORPS, Final FRCR | 1   |
| Skills  |                        |     |
| Identifies landmarks, key structures including vessels, lymph nodes on CT and MRI | CbD, DORPS, Final FRCR | 1   |
| Interprets X-ray, CT, MRI and PET imaging   | CbD, DORPS, Final FRCR | 1   |

### 4.2 Diagnosis and staging

| 4.2 Diagnosis and staging   |                                |     |
|---|--------------------------------|-----|
| To be able to diagnose and stage cancer.  |                                |     |
| Level   |                                |     |
| Group A – Core Group B – Intermediate   |                                |     |
| Group C – Intermediate Group D – Advanced   |                                |     |
| Knowledge   | Assessment<br>Methods          | GMP |
| Discusses the epidemiology and aetiology of the cancer, including:  |                                |     |
| <ul> <li>the general principles of tumour biology</li> </ul>  |                                |     |
| <ul> <li>the genetics of normal and malignant cells</li> </ul>  | First FRCR                     | 1   |
| the causation of human cancers  |                                |     |
| <ul> <li>the normal and aberrant mechanisms of cell growth control</li> </ul>   |                                |     |
| Describes the indications for urgent referral by GP   | CbD                            | 1,2 |
| Describes the staging and prognostic indices  | CbD, Final FRCR                | 1   |
| Describes the pathological techniques available and limitations of histology and immunohistochemistry and other specialist techniques, e.g. molecular biological techniques | First FRCR, CbD,<br>Final FRCR | 1   |
| Skills  |                                |     |
| Performs a focussed history and examination   | CbD, mini-CEX                  | 1,3 |
| Recommends appropriate diagnostic and staging investigations  | CbD                            | 1,2 |
|   |                                |     |

### **Behaviours**

See Sections 1.2, 1.3 and 1.4

# 4.3 Prognosis

| Assessment<br>Methods          | GMP  |
|--------------------------------|--|
| CbD, Final FRCR,<br>First FRCR | 1  |
|                                |  |
| CbD, Final FRCR,<br>First FRCR | 1  |
|                                |  |
|                                |  |
|                                | Methods CbD, Final FRCR, First FRCR CbD, Final FRCR, |

### 4.4 Genetics

To be able to assess if there is a significant genetic basis for the cancer.

| eν |  |
|----|--|
|    |  |

Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced

| Knowledge   | Assessment<br>Methods | GMP   |
|---|-----------------------|-------|
| Describes the principles of cancer genetics   | First FRCR            | 1     |
| Describes the features of the personal and family medical history that indicate a high risk of a genetic basis of the disease | CbD, First FRCR       | 1     |
| Describes when referral for genetic counselling is appropriate  | CbD, Final FRCR       | 1     |
| Explains how a gene abnormality affects the patient's prognosis   | CbD, Final FRCR       | 1     |
| Recognises the impact that discovery of a genetic abnormality may have on the patient and his/her family                      | CbD, Final FRCR       | 1     |
| Skills  |                       |       |
| Acquires an accurate family history   | CbD, mini-CEX         | 1,3,4 |
| Discusses the possibility of referral for genetic counselling with the patient  | mini-CEX              | 1,3,4 |
| Explains to the patient how the treatment options may be altered by a genetic abnormality                                     | mini-CEX              | 1,3,4 |
| Behaviours  |                       |       |
| See sections 1.3, 1.4, 1.5 and 1.10   |                       |       |
| Demonstrates willingness to facilitate patient choice regarding decision to undergo genetic testing                           | mini-CEX, MSF         | 3,4   |

## 4.5 Discussion of treatment options

| 4.5 Discussion of freatment options   |                           |       |
|---|---------------------------|-------|
| To be able to discuss treatment options in the light of understanding       | of the prognosis.         |       |
| Level   |                           |       |
| Group A – Core Group B – Intermediate                                       |                           |       |
| Group C – Advanced Group D – Advanced                                       |                           |       |
| Knowledge   | Assessment<br>Methods     | GMP   |
| Predicts the effects of treatment on prognosis                              | CbD, Final FRCR           | 1     |
| Recognises when radical and when palliative treatments are appropriate      | CbD, Final FRCR           | 1     |
| Skills  |                           |       |
| Informs patients of treatment options and discusses individual risk/benefit | CbD, Final FRCR, mini-CEX | 1,3,4 |
| Communicates appropriately with a wide variety of patients including:       |                           |       |
| working with interpreters to deal with patients from diverse backgrounds    | mini-CEX, MSF             | 3,4   |
| communicating with patients with special educational needs and their carers |                           |       |
| Behaviours  |                           |       |

### 4.6 Multi-disciplinary team (MDT) meetings

See sections 1.3, 1.4, 1.5 and 1.11

| 4.6 Multi-disciplinary team (MDT) meetings  |                       |     |  |
|---|-----------------------|-----|--|
| To be able to take part in discussions in tumour-site specific MDT meetings.                      |                       |     |  |
| Level   |                       |     |  |
| Group A – Core Group B – Intermediate   |                       |     |  |
| Group C – Advanced Group D – Advanced   |                       |     |  |
| Knowledge   | Assessment<br>Methods | GMP |  |
| Describes the indications for treatment and the risks and benefits of different treatment options | CbD, Final FRCR       | 1,2 |  |
| Describes the results of major randomised trials that have influenced present practice            | CbD, Final FRCR       | 1   |  |
| Describes major national guidelines   | CbD, Final FRCR       | 1   |  |
| Skills  |                       |     |  |
| Assesses potential risks and benefits of treatment options for the individual patient             | CbD, Final FRCR       | 1,2 |  |
| Discusses treatment options within the MDT meeting  | CbD, Final FRCR       | 1,3 |  |
| Behaviours  |                       |     |  |
| See sections 1.3, 1.4, 1.6, 1.9, 1.10 and 1.17  |                       |     |  |

### 4.7 Evaluating research

| 4.7 Evaluating rese                                    | earcn                                       |                                      |       |
|--|---|--------------------------------------|-------|
| To be able to evaluate and                             | synthesise research evidence to change      | practice.                            |       |
| Level  |   |                                      |       |
| Group A – Advanced                                     | Group B – Advanced                          |                                      |       |
| Group C – Advanced                                     | Group D – Advanced                          |                                      |       |
| Knowledge  |   | Assessment<br>Methods                | GMP   |
| Evaluates the published res                            | search evidence                             | CbD, Final FRCR,<br>Audit assessment | 1     |
| Evaluates ongoing trials of                            | both radiotherapy and systemic therapy      | CbD, Final FRCR<br>Audit assessment  | 1     |
| Evaluates the national and                             | international guidelines including NICE     | CbD, Final FRCR<br>Audit assessment  | 1     |
| Skills   |   |                                      |       |
| Discusses evidence at MD7                              | Γ with regard to specific patients          | CbD                                  | 1,2,3 |
| Discusses involvement in c                             | linical trials with colleagues              | CbB                                  | 1,2,3 |
| Revises or develops depart<br>the management of tumour | mental, evidence based guidelines for sites | CbD, Audit assessment                | 1,2,3 |
| Formulates plans to introdu department                 | ce new treatments and techniques to a       | CbD, Audit assessment                | 1,2,3 |
| Behaviours   |   |                                      |       |
| See sections 1.3, 1.7, 1.16,                           | 1.17, 1.18 and 1.21                         |                                      |       |

# 4.8 First line chemotherapy

To be able to assess patients for first line chemotherapy.

### Level

Group A – Core Group B – Intermediate
Group C – Advanced Group D – Advanced

| Knowledge  | Assessment<br>Methods                                  | GMP     |
|--|--|---------|
| Describes the mode of action of cytotoxic drugs and the principles of clinical use of systemic therapies | First FRCR   | 1       |
| Discusses the principles of pharmacokinetics and pharmacodynamics  | First FRCR   | 1       |
| Describes drug protocols   | DOST, mini-CEX,<br>CbD, Final FRCR,                    | 1       |
| Evaluates the benefits and toxicity of chemotherapy  | First FRCR, DOST,<br>mini-CEX, CbD, Final<br>FRCR, MSF | 1,2,4   |
| Decides which regimes are appropriate in the clinical situation  | DOST, mini-CEX,<br>CbD, Final FRCR,<br>MSF             | 1,2,4   |
| Describes tests, procedures or other arrangements required prior to therapy                              | DOST, mini-CEX,<br>CbD, Final FRCR,<br>MSF             | 1,2     |
| Skills   |  |         |
| Elicits the patient's wishes with regard to the aims of treatment  | DOST, mini-CEX,<br>CbD, MSF                            | 1,2,3,4 |
| Performs an appropriate history & examination  | DOST, mini-CEX,<br>Final FRCR,                         | 1,2,4   |
| Assesses performance status and evaluates the information to inform the treatment plan                   | DOST, mini-CEX,<br>Final FRCR,                         | 1,2,3,4 |
| Behaviours   |  |         |
| See sections 1.3, 1.4 and 1.5  |  |         |

# 4.9 Discussing treatment options

| To be able to discuss treatment options in the light of understanding of the prognosis. |  |  |         |
|---|--|--|---------|
| Level   |  |  |         |
| Group A – Core<br>Group C – Advanced  | Group B – Intermediate<br>Group D – Advanced |  |         |
| Knowledge   |  | Assessment<br>Methods                              | GMP     |
| Describes the acute ar  | nd long term risks of chemotherapy           | DOST, CbD,<br>mini-CEX, First FRCR,<br>Final FRCR, | 1,2,3,4 |
| Describes the aims of treatment and the prognosis                                       |  | DOST, CbD, mini-<br>CEX, Final FRCR,               | 1,3,4   |
| Skills  |  |  |         |
| Explains these issues   | and the risk/benefit ratio to the patient    | mini-CEX, DOST, PS                                 | 1,2,3,4 |
| Completes the consent form accurately with the patient                                  |  | mini-CEX, DOST                                     | 1,2,3,4 |
| Behaviours  |  |  |         |
| See sections 1.3, 1.4,  | 1.5 and 1.11                                 |  |         |

## 4.10 Initiating chemotherapy

| 4.10 Initiating chemotherapy  |                         | 1   |
|---|-------------------------|-----|
| To be able to prescribe the first course of chemotherapy.   |                         |     |
| Level   |                         |     |
| Group A – Core Group B – Intermediate   |                         |     |
| Group C – Advanced Group D – Advanced   |                         |     |
| Knowledge   | Assessment<br>Methods   | GMP |
| Describes the soute and long term side affects of the   | DOST, CbD,              |     |
| Describes the acute and long term side effects of the chemotherapy  | First FRCR, Final FRCR, | 1,2 |
| Describes the importance of biochemical, haematological and   | DOST, CbD,              |     |
| radiological parameters in determining dose of chemotherapy   | First FRCR, Final FRCR, | 1,2 |
| Describes the supportive measures both pharmacological and non-   | DOST, CbD,              |     |
| pharmacological to treat toxic effects of chemotherapy  | First FRCR, Final FRCR, | 1,2 |
| Skills  |                         |     |
| Generates an appropriate systemic therapy prescription which is safe, accurate and meets local and national standards | DOST, MSF               | 1,2 |
| Behaviours  |                         |     |
| See sections 1.5  |                         |     |

# 4.11 Managing patients receiving chemotherapy

To be able to manage patients undergoing radical and palliative chemotherapy treatment regimens.

### Level

 $\begin{array}{ll} \text{Group A} - \text{Core} & \text{Group B} - \text{Intermediate} \\ \text{Group C} - \text{Advanced} & \text{Group D} - \text{Advanced} \end{array}$ 

| Knowledge   | Assessment<br>Methods                    | GMP     |
|---|--|---------|
| Describes the physiology of haemopoiesis  | First FRCR                               | 1       |
| Describes the clinical pharmacology and uses of steroids and anti-<br>emetics                               | First FRCR                               | 1       |
| Describes the acute and long term side-effects of chemotherapy  | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1,2     |
| Describes how to assess tumour response   | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1       |
| Skills  |  |         |
| Develops a management plan for the patient during the chemotherapy including the management of side effects | DOST, CbD,<br>Final FRCR                 | 1,2,3   |
| Prescribes supportive treatments  | DOST, CbD,<br>Final FRCR                 | 1,2     |
| Judges when to stop or continue treatment   | DOST, CbD,<br>Final FRCR, MSF            | 1,2,3,4 |
| Behaviours  |  |         |
| See sections 1.3, 1.4 and 1.5   |  |         |

# 4.12 Initiating hormonal therapy

| To be able to assess patients for treatment and prescribe hormonal therapy  |                                      |       |
|---|--------------------------------------|-------|
| Level   |                                      |       |
| Group A – Core Group B – Intermediate   |                                      |       |
| Knowledge   | Assessment Methods                   | GMP   |
| Describes common drug protocols   | DOST, CbD, Final<br>FRCR             | 1     |
| Evaluates the benefits and toxicity of treatment  | DOST, CbD, First<br>FRCR, Final FRCR | 1,2   |
| Decides which regimes are appropriate in the clinical situation   | DOST, CbD, Final FRCR                | 1,2,3 |
| Describes the tests, procedures and other arrangements required prior to and during therapy                           | DOST, CbD, Final FRCR                | 1,2   |
| Skills  |                                      |       |
| Elicit the patient's wishes with regard to the aims of treatment  | DOST, mini-CEX,<br>Final FRCR, PS    | 3     |
| Performs an appropriate history and examination   | DOST, mini-CEX,<br>Final FRCR        | 1,3,4 |
| Assesses performance status   | DOST, mini-CEX,<br>Final FRCR, CbD   | 1,3   |
| Generates an appropriate systemic therapy prescription which is safe, accurate and meets local and national standards | DOST, MSF                            | 1,2   |
| Behaviours  |                                      |       |
| See sections 1.3, 1.4 and 1.5   |                                      |       |

# 4.13 Managing patients receiving hormonal therapy

| To be able to manage patients undergoing hormonal therapy   |  |         |
|---|--|---------|
| Level   |  |         |
| Group A – Core Group B – Intermediate   |  |         |
| Knowledge   | Assessment<br>Methods                    | GMP     |
| Describes the acute and long term side-effects of hormonal therapy  | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1,2     |
| Describes how to assess tumour response   | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1       |
| Skills  |  |         |
| Develops a management plan for the patient during hormonal therapy including the management of side effects | DOST, CbD,<br>Final FRCR                 | 1,2,3   |
| Prescribes supportive treatments  | DOST, CbD,<br>Final FRCR                 | 1,2     |
| Judges when to stop or continue treatment   | DOST, CbD,<br>Final FRCR, MSF            | 1,2,3,4 |
| Behaviours  |  |         |
| See sections 1.3, 1.4 and 1.5   |  |         |

# 4.14 Assessing patients for biological therapy

To be able to assess patients for treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins.

### Level

| Group A – Core     | Group B – Intermediate |
|--------------------|------------------------|
| Group C - Advanced | Group D – Advanced     |

| Knowledge  | Assessment<br>Methods              | GMP   |
|--|------------------------------------|-------|
| Describes the principles of biological and novel therapies                       | First FRCR                         | 1     |
| Describes common drug protocols  | DOST, CbD, Final<br>FRCR           | 1     |
| Evaluates the benefits and toxicity of treatment                                 | DOST, CbD, Final FRCR              | 1,2   |
| Decides which regimes are appropriate in the clinical situation                  | DOST, CbD, Final FRCR              | 1,2,3 |
| Describes the tests, procedures and other arrangements required prior to therapy | DOST, CbD, Final<br>FRCR           | 1,2   |
| Skills   |                                    |       |
| Elicits the patient's wishes with regard to the aims of treatment                | DOST, mini-CEX,<br>Final FRCR, PS  | 3     |
| Performs an appropriate history and examination                                  | DOST, mini-CEX,<br>Final FRCR      | 1,3,4 |
| Assesses performance status  | DOST, mini-CEX,<br>Final FRCR, CbD | 1,3   |
| Behaviours   |                                    |       |
| See sections 1.3, 1.4 and 1.5  |                                    |       |

# 4.15 Consent for biological therapy

To be able to consent patients for treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins.

### Level

| Group A – Intermediate | Group B – Intermediate |
|------------------------|------------------------|
| Group C – Advanced     | Group D – Advanced     |

| Group C – Advanced Group D – Advanced   |  |         |
|---|--|---------|
| Knowledge   | Assessment<br>Methods                        | GMP     |
| Describes the acute and long term risks of treatment with monoclonal antibodies, tyrosine kinase inhibitors, interfero interleukins |  | 1       |
| Describes the aims of treatment and the prognosis   | DOST, CbD, Final<br>FRCR                     | 1       |
| Skills  |  |         |
| Explains about these issues and the risk/benefit ratio to the   | ne patient DOST, mini-CEX,<br>Final FRCR, PS | 1,2,3,4 |
| Completes the consent form accurately with the patient  | DOST,mini-CEX, PS                            | 1,2,3,4 |
| Behaviours  |  |         |
| See sections 1.3, 1.4, 1.5, 1.11 and 1.14   |  |         |

### 4.16 Initiating biological therapies

To be able to prescribe the first course of treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons and interleukins.

| ων |  |
|----|--|
|    |  |

| Group A – Core     | Group B – Intermediate |
|--------------------|------------------------|
| Group C - Advanced | Group D - Advanced     |

| Knowledge  | Assessment<br>Methods                    | GMP |
|--|--|-----|
| Describes the acute and long term side effects of the therapies  | DOST, CbD                                | 1,2 |
| Describes the importance of biochemical, haematological and radiological parameters in determining whether the treatment can be safely given | First FRCR, Final FRCR,                  | 1,2 |
| Describes the supportive measures both pharmacological and non-<br>pharmacological to treat toxic effects of therapy                         | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1,2 |
| Skills   |  |     |
| Generates an appropriate systemic therapy prescription which is safe, accurate and meets local and national standards                        | DOST, MSF                                | 1,2 |
| Behaviours   |  |     |
| See sections 1.3, 1.4 and 1.5  |  |     |

### 4.17 Managing patients receiving biological therapies

To be able to manage patients undergoing treatment with monoclonal antibodies, tyrosine kinase inhibitors, interferons and interleukins.

### Level

Group A – Core Group B – Intermediate
Group C – Advanced Group D – Advanced

| Group C – Advanced Group D – Advanced  |  |         |
|--|--|---------|
| Knowledge  | Assessment<br>Methods                    | GMP     |
| Describes the acute and long term side-effects of these therapies  | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1,2     |
| Describes how to assess tumour response  | DOST, CbD,<br>First FRCR, Final<br>FRCR, | 1       |
| Skills   |  |         |
| Develops a management plan for the patient during the administration of the therapy including the management of side effects | DOST, CbD,<br>Final FRCR                 | 1,2,3   |
| Prescribes supportive treatments   | DOST, CbD,<br>Final FRCR                 | 1,2     |
| Judges when to stop or continue treatment  | DOST, CbD,<br>Final FRCR, MSF            | 1,2,3,4 |
| Behaviours   |  |         |
| See sections 1.3, 1.4 and 1.5  |  |         |

# 4.18 Assessing patients for radiotherapy

| To be able to assess patients for radical and palliative radiotherapy. |
|--|
| Level  |

| Group A – Core | Group B – Intermediate |
|----------------|------------------------|

Group C – Advanced Group D – Advanced

| Knowledge   | Assessment<br>Methods                | GMР   |
|---|--------------------------------------|-------|
| Discusses basic physics relevant to radiotherapy, electromagnetic radiation and sub atomic particles and their interactions of with matter. | First FRCR                           | 1     |
| Discusses the indications for radiotherapy  | DORPS, CbD, Final FRCR               | 1     |
| Describes its side effects  | DOST, CbD, First<br>FRCR, Final FRCR | 1,2   |
| Evaluates the benefits and toxicity of treatment  | DORPS, CbD, Final FRCR               | 1,2,3 |
| Describes tests, procedures or other arrangements required prior to therapy   | DORPS, CbD, Final FRCR               | 1,2   |
| Skills  |                                      |       |
| Elicit the patient's wishes with regard to the aims of treatment  | DORPS, mini-CEX,<br>Final FRCR, PS   | 3     |
| Performs an appropriate history and examination   | DORPS, mini-CEX,<br>Final FRCR       | 1,3,4 |
| Assess performance status and use the information to inform the treatment plan  | DORPS, mini-CEX,<br>Final FRCR, CbD  | 1,3   |
| Behaviours  |                                      |       |
| See sections 1.3, 1.4 and 1.5   |                                      |       |

# 4.19 Consent for radiotherapy

To be able to obtain informed consent from patients for radiotherapy.

### Level

| Group A – Core<br>Group C – Advanced                            | Group B – Intermediate Group D – Advanced |                                       |         |
|---|---|---------------------------------------|---------|
| Knowledge   |   | Assessment<br>Methods                 | GMP     |
| Describes the acute an  | nd long term risks of radiotherapy        | DORPS, CbD, First<br>FRCR, Final FRCR | 1       |
| Discusses the aims of treatment and the prognosis               |   | DORPS, CbD, Final FRCR                | 1       |
| Skills  |   |                                       |         |
| Explains these issues a   | and the risk/benefit ratio with patients  | DORPS, mini-CEX,<br>Final FRCR, PS    | 1,2,3,4 |
| Completes the informed consent form accurately with the patient |   | DORPS,mini-CEX, PS                    | 1,2,3,4 |
| Behaviours  |   |                                       |         |
| See sections 1.3, 1.4,  | 1.5, 1.11 and 1.14                        |                                       |         |

### 4.20 Radiotherapy treatment strategy

To be able to develop a radiotherapy treatment strategy.

### Level

 $\begin{array}{ll} \mbox{Group A-Core} & \mbox{Group B-Intermediate} \\ \mbox{Group C-Advanced} & \mbox{Group D-Advanced} \end{array}$ 

| Knowledge  | Assessment<br>Methods | GMP   |
|--|-----------------------|-------|
| Describes the principles of radiation dosimetry, the physics of teletherapy beams (x-rays), electron beam physics and radiotherapy planning  | First FRCR            | 1     |
| Describes the patient position and immobilization technique  | DORPS, Final FRCR     | 1     |
| Describes the method of tumour localisation  | DORPS, Final FRCR     | 1     |
| Evaluates the benefits and risks of the possible radiotherapy delivery techniques including consideration of beam arrangements static and rotational IMRT and SABR  Describes the indications and aims of IGRT and evaluates the | DORPS, Final FRCR     | 1     |
| methods available  | DORPS, Final FRCR     | 1     |
| Skills   |                       |       |
| Communicate effectively to the planning radiographers the imaging and treatment strategy   | DORPS, MSF            | 1,2,3 |
| Records all aspects of the planning process clearly  | DORPS,CbD             | 1,2,3 |
| Behaviours   |                       |       |
| See sections 1.6, 1.7, and 1.9   |                       |       |

# 4.21 Radiotherapy treatment volume

To be able to determine the gross tumour volume (GTV), clinical target volume (CTV), internal target volume (ITV), planning target volume (PTV), organs at risk (OAR) and planning organs at risk volume (PRV) as appropriate for radiotherapy.

### Level

Group A – Core Group B – Intermediate
Group C – Advanced Group D – Advanced

| Group C – Advanced Group D – Advanced   |                                |     |
|---|--------------------------------|-----|
| Knowledge   | Assessment<br>Methods          | GMP |
| Interprets diagnostic imaging (including CT, PET and MRI  | DORPS, Final FRCR              | 1   |
| Describes the use of cross-sectional imaging in planning  | DORPS, Final FRCR              | 1   |
| Discusses the clinical and radiological parameters associated with planning 2-D, 3-D, 4-D conformal radiotherapy and IMRT | DORPS, Final FRCR              | 1   |
| Specifies the dose and tissue constraint for the organs at risk.  | DORPS,First FRCR<br>Final FRCR | 1,2 |
| Skills  |                                |     |
| Defines GTV, CTV, ITV and PTV   | DORPS, Final FRCR              | 1   |
| Defines organs at risk, outlines them and defines planning organs at risk volume (PRV)                                    | DORPS, Final FRCR              | 1,2 |
| Defines DVH planning constraints  | DORPS, Final FRCR              | 1,2 |

| Balances tumour control against potential damage to organs at risk Explains changes in dose constraints depending on dose per fraction based on application of radiobiology and tolerance doses | DORPS, Final FRCR<br>DORPS, Final FRCR | 1,2<br>1,2 |
|---|--|------------|
| Behaviours  |  |            |
| See sections 1.5 and 1.6  |  |            |

4.22 Radiotherapy treatment plan

| To be able to evaluate a radiotherapy treatment plan.  |                       |     |  |  |
|--|-----------------------|-----|--|--|
| Level  |                       |     |  |  |
| Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced                      |                       |     |  |  |
| Knowledge  | Assessment<br>Methods | GMP |  |  |
| Describes the ICRU guidelines  | DORPS, Final FRCR     | 1   |  |  |
| Skills   |                       |     |  |  |
| Assesses critically the dose distribution within the treatment volume and organs at risk         | DORPS, Final FRCR     | 1,2 |  |  |
| Evaluates whether a treatment plan is adequate and develops ways of improving an inadequate plan | DORPS, Final FRCR     | 1   |  |  |
| Behaviours   |                       |     |  |  |
| See sections 1.5   |                       |     |  |  |

## 4.23 Prescribing palliative radiotherapy

| 4.23 FIESCHBING  | y pamanye radiomerapy  |                       |     |
|--|--|-----------------------|-----|
| To be able to prescribe  | To be able to prescribe appropriate dose and fractionation schedule for palliative radiotherapy. |                       |     |
| Level  |  |                       |     |
| Group A – Core   | Group B – Intermediate   |                       |     |
| Group C – Advanced   | Group D – Advanced   |                       |     |
| Knowledge  |  | Assessment<br>Methods | GMP |
| Describes the general principles of radiobiology, including normal tissue and population radiobiology                                    |  | First FRCR            | 1   |
| Describes dose/fractionation schedules in common use.  |  | DORPS, Final FRCR     | 1   |
| Skills   |  |                       |     |
| Decides an appropriate treatment schedule according to stage of disease, performance status of patients and concomitant systemic therapy |  | DORPS, Final FRCR     | 1,2 |
| Behaviours   |  |                       |     |
| See sections 1.3, 1.4,1  | l.5 and 1.6  |                       |     |
|  |  |                       |     |

### 4.24 Prescribing radical radiotherapy

To be able to prescribe appropriate dose and fractionation schedule for radical radiotherapy. Level Group A – Intermediate Group B – Intermediate Group C - Advanced Group D - Advanced Assessment Knowledge **GMP Methods** Lists the parameters that should be included when writing a First FRCR 1 radiotherapy prescription DORPS, Final FRCR Describes dose/fractionation schedules in common use. 1 **Skills** Decides an appropriate treatment schedule according to stage of disease, performance status of patients and concomitant systemic DORPS, Final FRCR 1,2 therapy **Behaviours** See sections 1.3, 1.4,1.5 and 1.6

| 4.25 Modifying r   | radiotherapy for individual patients   |                                    |     |  |
|--|--|------------------------------------|-----|--|
| To be able to modify tr  | To be able to modify treatment plans according to patient's individual needs, pre-morbid conditions etc. |                                    |     |  |
| Level  |  |                                    |     |  |
| Group A – Core   | Group B – Intermediate   |                                    |     |  |
| Group C – Advanced   | Group D – Advanced   |                                    |     |  |
| Knowledge  |  | Assessment<br>Methods              | GMP |  |
| Describes normal tissu definition.   | ue morbidity and its impact on target volume   | CbD, DORPS, First FRCR, Final FRCR | 1,2 |  |
| Describes risks of re-treatment with radiation based on normal tissue tolerance limits     |  | CbD, DORPS, First FRCR, Final FRCR | 1,2 |  |
| Skills   |  |                                    |     |  |
| Judges how to modify morbidity   | treatment plans based on patient's co-   | CbD, DORPS, Final FRCR             | 1,2 |  |
| Assesses when re-treatment is acceptable and prescribes appropriate dose and fractionation |  | CbD, DORPS, Final FRCR             | 1,2 |  |
| Behaviours   |  |                                    |     |  |
| See sections 1.3, 1.4 a  | and 1.5  |                                    |     |  |

### 4.26 Verifying radiotherapy treatments

| 4.20 Vernying radiotherapy treathlents   |                           |     |
|--|---------------------------|-----|
| To be able to verify a treatment plan.   |                           |     |
| Level  |                           |     |
| Group A – Core Group B – Intermediate  |                           |     |
| Group C – Advanced Group D – Advanced  |                           |     |
| Knowledge  | Assessment<br>Methods     | GMP |
| Describes the processes that may be used to ensure that the radiotherapy prescription is correctly implemented | First FRCR                | 1,2 |
| Describes the use of digitally reconstructed radiographs   | CbD, DORPS, Final FRCR    | 1,2 |
| Describes the use of portal imaging  | CbD, DORPS, Final FRCR    | 1,2 |
| Discusses the quality assurance of IMRT plans  | CbD, DORPS, Final FRCR    | 1,2 |
| Describes the type of IGRT techniques (planar and volumetric) and the value of each approach                   | CbD, DORPS, Final<br>FRCR | 1,2 |
| Skills   |                           |     |
| Assesses accuracy of patient set-up and recommends adjustments   | CbD, DORPS, Final<br>FRCR | 1,2 |
| Behaviours   |                           |     |
|  |                           |     |

# 4.27 Principles of Proton Therapy

See section 1.5

| To be aware of the principles and clinical implications of proton therapy |  |                           |     |
|---|--|---------------------------|-----|
| Level   |  |                           |     |
| Group A – Intermediate<br>Group C – Intermediate                          | Group B – Intermediate<br>Group D – Advanced |                           |     |
| Knowledge   |  | Assessment<br>Methods     | GMP |
| Describes the theoretical benefits and risks of proton therapy            |  | CbD, DORPS, Final<br>FRCR | 1   |
| Discusses the indications for proton therapy                              |  | CbD, DORPS, Final FRCR    | 1,2 |

# 4.28 Clinical implications of brachytherapy

To be aware of the clinical implications of brachytherapy using sealed and unsealed sources.

| Group A – Intermediate | Group B – Intermediate |
|------------------------|------------------------|
| Group C – Intermediate | Group D - Advanced     |

| Knowledge   | Assessment<br>Methods                 | GMP |
|---|---------------------------------------|-----|
| Describes the principles of radiotherapy physics related brachytherapy                  | DORPS, First FCR                      | 1,2 |
| Discusses the indications for and aims of treatment                                     | CbD, DORPS, First<br>FRCR, Final FRCR | 1,2 |
| Describes the methods available   | CbD, DORPS, First<br>FRCR, Final FRCR | 1,2 |
| Describes the acute and long term toxicities and can discuss the organs at risk         | CbD, DORPS, First<br>FRCR, Final FRCR | 1,2 |
| Describes the principles of dose prescription   | CbD, DORPS, First<br>FRCR, Final FRCR | 1,2 |
| Describes the radiation protection issues   | CbD, DORPS, First FRCR, Final FRCR    | 1,2 |
| Recognises requirement for ARSAC certificate  | CbD, DORPS, mini-<br>CEX              | 1,2 |
| Skills  |                                       |     |
| Applies radiation protection principles when assessing patients receiving brachytherapy | CbD, DORPS, Final FRCR                | 1,2 |
| Behaviours  |                                       |     |
| See sections 1.3, 1.4,1.5 and 1.6   |                                       |     |

# 4.29 Performing a brachytherapy procedure

To be able to perform a brachytherapy procedure using sealed sources.

| $\boldsymbol{\alpha}$ |  |
|-----------------------|--|
|                       |  |

| Group A – Advanced | Group B – Advanced |
|--------------------|--------------------|
| Group C – Advanced | Group D - Advanced |

| Knowledge   | Assessment<br>Methods             | GMР     |
|---|-----------------------------------|---------|
| Describes the relevant anatomy  | CbD, DORPS, mini-<br>CEX          | 1,2     |
| Describes the appropriate investigations prior to and after treatment   | CbD, DORPS, mini-<br>CEX          | 1,2     |
| Describes the patient position and any appropriate immobilisation techniques  | CbD, DORPS, mini-<br>CEX          | 1,2     |
| Discusses the radiation protection issues.  | CbD, DORPS, mini-<br>CEX          | 1,2     |
| Describes the concomitant therapies to reduce or treat toxicity   | CbD, DORPS, mini-<br>CEX          | 1,2     |
| Recognises requirement for ARSAC certificate  | CbD, DORPS, mini-<br>CEX          | 1,2     |
| Skills  |                                   |         |
| Assesses individual patients and balances the benefits against the risks  | CbD, DORPS, mini-<br>CEX          | 1,2,3,4 |
| Elicit the patient's wishes with regard to the aims of treatment  | CbD, DORPS, mini-<br>CEX, PS      | 1,2,3,4 |
| Explains the aims and risks to the patient and takes informed consent   | CbD, DORPS, mini-<br>CEX, PS      | 1,2,3,4 |
| Communicate effectively with the radiographers, physicists, theatre staff, ward nurses with regards to the appropriate imaging and treatment strategy | CbD, DORPS, mini-<br>CEX, MSF, PS | 1,2,3,4 |
| Records all aspects of the process clearly  | CbD, mini-CEX, MSF                | 1,2,3   |
| Performs the procedure correctly  | CbD, mini-CEX, MSF                | 1,2     |
| Prescribes the radiation dose balancing tumour control against potential damage to the organs at risk   | CbD, DORPS, mini-<br>CEX, MSF     | 1,2     |
| Supports the patient through the treatment and side effects   | CbD, mini-CEX, MSF, PS            | 1,2,3,4 |
| Advises the patient, their relatives and staff with regard to radiation protection issues   | CbD, DORPS, mini-<br>CEX, MSF, PS | 1,2,3,4 |
| Liaises with the radiation protection advisor, including radiation protection supervisors and medical physics experts                                 | CbD, DORPS, mini-<br>CEX, MSF,    | 1,2,3   |
| Behaviours  |                                   |         |
| See sections 1.3, 1.4.1.5, 1.6 and 1.9  |                                   |         |

See sections 1.3, 1.4,1.5, 1.6 and 1.9

### Prescribing brachytherapy using an unsealed source

To be able to prescribe brachytherapy using an unsealed source. Level Group A – Advanced Group B – Advanced Group C - Advanced Group D - Advanced Assessment **GMP** Knowledge **Methods** Describes the appropriate investigations prior to and after CbD, DORPS, mini-1,2 treatment CEX CbD, First FCR, mini-1,2 Discusses the radiation protection issues CEX CbD, DORPS, mini-Describes the concomitant therapies to reduce or treat toxicity 1,2 CEX CbD, First FRCR, Recognises the requirement for an ARSAC certificate 1,2 mini-CEX **Skills** Assesses individual patients and balances the benefits against the CbD, mini-CEX 1,2,3,4 Elicits the patient's wishes with regard to the aims of treatment CbD, mini-CEX, PS 1,2,3,4 Explains the aims and risks to the patient and takes informed CbD, mini-CEX, PS 1,2,3,4 consent Communicates effectively with the planning radiographers, CbD, DORPS, mini-1,2,3,4 physicists and ward nurses as appropriate the treatment strategy CEX, MSF, PS CbD, DORPS, mini-Records all aspects of the process clearly 1,2,3 CEX, MSF Administers the isotope safely CbD, mini-CEX, MSF 1,2 Prescribes the dose balancing tumour control against potential CbD, DORPS, mini-1,2 damage to the organs at risk CEX, MSF CbD, mini-CEX, MSF, Supports the patient through the treatment and side effects 1,2,3,4 PS Advises the patient, their relatives and staff with regard to radiation CbD, mini-CEX, MSF, 1,2,3,4 protection issues PS Liaises with the radiation protection advisor, including radiation CbD, mini-CEX, MSF, 1,2,3 protection supervisors and medical physics experts

### **Behaviours**

See sections 1.3, 1.4,1.5, 1.6 and 1.9

### 4.31 Assessing and managing patients undergoing radiotherapy

|  | ig and managing panome andorgonic            |  |     |
|--|--|--|-----|
| To be able to asses                                    | s and manage patients undergoing radiotherap | y.                                       |     |
| Level  |  |  |     |
| Group A – Core<br>Group C – Core                       | Group B – Core<br>Group D – Advanced         |  |     |
| Knowledge  |  | Assessment<br>Methods                    | GMP |
| Describes early rea                                    | ctions to radiotherapy and their management  | CbD, First FRCR,<br>Final FRCR, mini-CEX | 1,2 |
| Skills   |  |  |     |
| Assesses and treats patients in an on-treatment clinic |  | CbD, Final FRCR,<br>mini-CEX, PS         | 1,2 |
| Behaviours   |  |  |     |
| See sections 1.3, 1.                                   | .4 and 1.5                                   |  |     |

# 4.32 Modifying a course of radiotherapy

To be able to modify a course of radiotherapy treatment for individual patients according to severity of

| reactions including adjustment for gaps in treatment.   | dai pationio docording to ot          | overky of |
|---|---------------------------------------|-----------|
| Level   |                                       |           |
| Group A – Intermediate Group B – Intermediate Group C – Advanced Group D – Advanced                                 |                                       |           |
| Knowledge   | Assessment<br>Methods                 | GMP       |
| Discusses how radiobiological principles impact on radical radiotherapy   | CbD, DORPS, First<br>FRCR, Final FRCR | 1,2       |
| Lists possible strategies for dealing with treatment gaps   | CbD, DORPS, First FRCR, Final FRCR    | 1,2       |
| Skills  |                                       |           |
| Judges how to modify a course of radiotherapy treatment depending on acute toxicity and unplanned gaps in treatment | CbD, DORPS, Final FRCR,               | 1,2       |
| Behaviours  |                                       |           |
| Soc sections 1.2. 1.4 and 1.5   |                                       |           |

See sections 1.3, 1.4 and 1.5

# 4.33 Assessing patients for combined modality therapy

| To be able to assess patients for combined modality therapy.  |  |         |
|---|--|---------|
| Level   |  |         |
| Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced                             |  |         |
| Knowledge   | Assessment<br>Methods                        | GMP     |
| Discusses the interaction between chemotherapy and radiotherapy (before, during or following radiation) | CbD, DORPS, First<br>FRCR                    | 1,2     |
| Discusses the circumstances in which combined modality therapy might be considered                      | CbD, DORPS, First FRCR, Final FRCR, mini-CEX | 1,2     |
| Skills  |  |         |
| Elicits the patient's wishes with regard to the aims of treatment                                       | CbD, DORPS, Final<br>FRCR, mini-CEX, PS      | 1,2,3,4 |
| Discusses the side effects and risk/benefit ratio with patients   | CbD, DORPS, Final FRCR, mini-CEX             | 1,2,3,4 |
| Behaviours  |  |         |
| See sections 1.3, 1.4,1.5, 1.6 and 1.17   |  |         |

| 4.34 Emerging techniques   |                       |              |
|--|-----------------------|--------------|
| To be able to discuss treatment with protons or neutrons   |                       |              |
| Level  |                       |              |
| Group A – Advanced Group B – Advanced  |                       |              |
| Group C – Advanced Group D – Advanced  |                       |              |
|  |                       |              |
| Knowledge  | Assessment<br>Methods | GMP          |
| Knowledge  Discusses the reasons why treatment with protons or neutrons treatments are sometimes desirable |                       | <b>GMP</b> 1 |

### Obtaining informed consent for clinical trials and maintaining research 4.35 records

To be able to consent patients for Phase II and Phase III trials and maintain appropriate research

| records.   |                        |                       |         |
|--|------------------------|-----------------------|---------|
| Level  |                        |                       |         |
| Group A – Core   | Group B – Intermediate |                       |         |
| Group C – Advanced   | Group D – Advanced     |                       |         |
| Knowledge  |                        | Assessment<br>Methods | GMP     |
| Discusses research etl   | nics                   | CbD, mini-CEX         | 1,2,3   |
| Describes Good Clinical Practice                               |                        | CbD, mini-CEX         | 1,2,3   |
| Skills   |                        |                       |         |
| Discusses option of entering a clinical trial with the patient |                        | CbD, mini-CEX         | 1,2,3,4 |
| Behaviours   |                        |                       |         |
| See sections 1.3, 1.14   | and 1.16               |                       |         |

# 4.36 Diagnosing relapse

| To be able to diagnose relapse.   |  |         |
|---|--|---------|
| Level   |  |         |
| Group A – Core Group B – Intermediate Group C – Intermediate Group D – Advanced                                       |  |         |
| Knowledge   | Assessment<br>Methods                    | GMP     |
| Describes the signs and symptoms, changes in tumours markers and imaging findings that may be associated with relapse | CbD, First FRCR,<br>Final FRCR, mini-CEX | 1,2     |
| Skills  |  |         |
| Performs an appropriate history and examination   | CbD, Final FRCR, mini-CEX, PS            | 1,2,3,4 |
| Decides on appropriate investigations for patients suspected of having relapsed                                       | CbD, Final FRCR,<br>mini-CEX, PS         | 1,2     |
| Interprets imaging (X-rays, CT, MRI, PET)   | CbD, Final FRCR, mini-CEX,               | 1,2     |
| Behaviours  |  |         |
| See sections 1.2, 1.3, 1.4 and 1.5  |  |         |

# 4.37 Developing a management plan for patients whose disease has relapsed

| nor Dovoroping   | 4.07 Developing a management plan for patients whose disease has relapsed   |                              |         |  |
|--|---|------------------------------|---------|--|
| To be able to develop a management plan for patients whose disease has relapsed. |   |                              |         |  |
| Level  |   |                              |         |  |
| Group A – Core   | Group B – Intermediate  |                              |         |  |
| Group C – Advanced   | Group D – Advanced  |                              |         |  |
| Knowledge  |   | Assessment<br>Methods        | GMP     |  |
| radiotherapy, chemoth kinase inhibitors, interf                                  | surgery, interventional radiology,<br>erapy, monoclonal antibodies, tyrosine<br>ferons, interleukins, symptom control and<br>ints with relapsed disease | CbD, Final FRCR,<br>mini-CEX | 1,2     |  |
| Skills   |   |                              |         |  |
| Flicits the nation's wishes with redard to the aims of treatment                 |   | CbD, Final FRCR,<br>mini-CEX | 1,2,3,4 |  |
| Behaviours   |   |                              |         |  |
| See sections 1.3, 1.4,   | 1.5, 1.6 and 1.11   |                              |         |  |
|  |   |                              |         |  |

# 4.38 Assessing patients for second and further lines of systemic anticancer therapy

To be able to assess patients for appropriate second and further lines of chemotherapy, monoclonal antibodies, tyrosine kinase inhibitors, interferons or interleukins.

### Level

Group A – Intermediate Group B – Intermediate Group C – Advanced Group D – Advanced

| Knowledge  | Assessment<br>Methods                            | GMP     |
|--|--|---------|
| Describes the molecular biology of chemotherapy drug resistance  | DOST, First FCR                                  |         |
| Discusses the role of 2 <sup>nd</sup> and further lines of chemotherapy and monoclonal antibodies, tyrosine kinase inhibitors, interferons, interleukins | CbD, First FRCR,<br>Final FRCR, mini-CEX         | 1,2     |
| Discusses different patient motives (coping, survival enhancement, improvement of quality of life)   | CbD, First FRCR,<br>Final FRCR, mini-<br>CEX, PS | 1,2     |
| Skills   |  |         |
| Assesses patient's fitness for treatments e.g., by performance status  | CbD, DOST, Final FRCR, mini-CEX, PS              | 1,2,3,4 |
| Prescribes common therapeutic regimes  | CbD, DOST, Final FRCR, mini-CEX, PS              | 1,2     |
| Assesses whether the outcomes of the therapy are meeting the patient's needs and discusses this with them  | CbD, DOST, Final FRCR, mini-CEX, PS              | 1,2,3,4 |
| Behaviours   |  |         |
| See sections 1.3, 1.4, 1.5, 1.6 and 1.11   |  |         |

# 4.39 Adjusting a chemotherapy regimen according to patient fitness

To be able to adjust choice of second and further lines of chemotherapy regimen according to patient fitness.

### Level

Group A – Intermediate Group B – Intermediate

Group C – Advanced Group D – Advanced

| Group C - Advanced Group D - Advanced  |                                 |       |
|--|---------------------------------|-------|
| Knowledge  | Assessment<br>Methods           | GMP   |
| Discusses the problems associated with treatment regimens in pre-<br>treated patients, the elderly, those with comorbidity and patients<br>with lower performance status | CbD, DOST, Final FRCR, mini-CEX | 1,2,3 |
| Skills   |                                 |       |
| Modifies treatment plan appropriately for individual patients  | CbD, DOST, Final<br>FRCR        | 1,2   |
| Judges when to continue or stop treatment  | CbD, DOST, Final FRCR           | 1,2   |
| Behaviours   |                                 |       |
| See sections 1.3, 1.4, 1.5, 1.6 and 1.11   |                                 |       |

# 4.40 Assessing response to second and subsequent lines of chemotherapy

| To be able to assess response to second and subsequent lines of chemotherapy. |                          |     |  |
|---|--------------------------|-----|--|
| Level   |                          |     |  |
| Group A – Core Group B – Intermediate Group C – Advanced Group D – Advanced   |                          |     |  |
| Knowledge   | Assessment<br>Methods    | GMP |  |
| Discusses the aims of treatment   | CbD, DOST, Final<br>FRCR | 1,2 |  |
| Skills  |                          |     |  |
| Assesses response according to RECIST criteria                                | CbD, DOST, Final<br>FRCR | 1,2 |  |
| Behaviours  |                          |     |  |
| See sections 1.3, 1.4 and 1.5   |                          |     |  |

# 4.41 Recognising when further chemotherapy is inappropriate

| To be able to recognise when further or continuing chemotherapy is inappropriate.                      |  |         |  |
|--|--|---------|--|
| Level  |  |         |  |
| Group A – Intermediate Group B – Intermediate<br>Group C – Advanced Group D – Advanced                 |  |         |  |
| Knowledge  | Assessment<br>Methods                  | GMP     |  |
| Discusses the palliative options available to a patient who is not responding to /tolerating treatment | CbD, Final FRCR, mini-CEX              | 1,2     |  |
| Skills   |  |         |  |
| Communicates bad news to the patient and their relatives   | CbD, DOST, Final<br>FRCR, mini-CEX, PS | 1,2,3,4 |  |
| Negotiates stopping treatment with the patient and their relatives                                     | CbD, DOST, Final FRCR, mini-CEX, PS    | 1,2,3,4 |  |
| Organises palliative supportive care   | CbD, DOST, Final FRCR, mini-CEX        | 1,2     |  |
| Behaviours   |  |         |  |
| See sections 1.3, 1.4, 1.5, 1.6 and 1.11   |  |         |  |

# 4.42 Assessing patients with relapsed cancer for palliative radiotherapy

| To be able to assess p               | atients with relapsed cancer for palliative rad | liotherapy.  |         |
|--------------------------------------|---|--|---------|
| Level                                |   |  |         |
| Group A – Core<br>Group C – Advanced | Group B – Intermediate<br>Group D – Advanced    |  |         |
| Knowledge                            |   | Assessment<br>Methods                              | GMP     |
| Discusses the radiobio appropriate   | logical consequences of retreatment if          | CbD, DORPS,<br>First FRCR, Final<br>FRCR, mini-CEX | 1,2     |
| Skills                               |   |  |         |
| Elicits the patient's wis            | hes with regard to the aims of treatment        | CbD, DORPS,<br>Final FRCR, mini-<br>CEX, PS        | 1,2,3,4 |
| Discusses the role of rapatients     | adiotherapy and risk/benefit with individual    | CbD, DORPS,<br>Final FRCR, mini-<br>CEX, PS        | 1,2,3,4 |
| Behaviours                           |   |  |         |
| See sections 1.3, 1.4,               | 1.5 and 1.11                                    |  |         |

# 4.43 Identifying when patients with relapsed disease require referral to another specialty

| specialty  |  |                                  |         |  |
|--|--|----------------------------------|---------|--|
| To be able to identify when pa   | To be able to identify when patients with relapsed disease require referral to another speciality. |                                  |         |  |
| Level  |  |                                  |         |  |
| · ·  | p B – Intermediate<br>p D – Advanced   |                                  |         |  |
| Knowledge  |  | Assessment<br>Methods            | GMP     |  |
| Describes the indications for shigh dose chemotherapy with transplantation | surgical, radiological intervention and autologous or allogeneic                                   | CbD, Final FRCR,                 | 1,2     |  |
| Skills   |  |                                  |         |  |
| Elicits the patient's wishes wit   | th regard to the aims of treatment   | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |  |
| Develops an appropriate treat  | tment plan for individual patients   | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |  |
| Behaviours   |  |                                  |         |  |
| See sections 1.3, 1.4, 1.5, 1.6  | 3 and 1.9  |                                  |         |  |

# 4.44 Managing physical symptoms of patients with relapsed cancer

To be able to manage the physical symptoms of patients with relapsed cancer.

| $\boldsymbol{\alpha}$ |  |
|-----------------------|--|
|                       |  |

| Group A – Core | Group B – Core     |
|----------------|--------------------|
| Group C – Core | Group D – Advanced |

| Group C – Core Group D – Advanced  |                                  |         |
|--|----------------------------------|---------|
| Knowledge  | Assessment<br>Methods            | GMP     |
| Outlines the clinical pharmacology of analgesics, steroids and antiemetics.  | CbD, First FRCR                  | 1,2     |
| Discusses the differential diagnosis of symptoms in patients with relapsed cancer both due to metastatic and the non-metastatic manifestations of malignancy | CbD, Final FRCR, mini-CEX        | 1,2     |
| Describes the appropriate investigations   | CbD, Final FRCR, mini-CEX        | 1,2     |
| Describes the treatment options available  | CbD, Final FRCR, mini-CEX        | 1,2     |
| Skills   |                                  |         |
| Performs a focused history and examination   | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |
| Discusses the options with the patient   | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |
| Advises the patient as to the management plan most likely to improve their symptoms  | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |
| Prescribes drugs for palliation of symptoms including in the last few days of life   | CbD, Final FRCR, mini-CEX        | 1,2,3,4 |
| Behaviours   |                                  |         |
| See sections 1.3, 1.4, 1.5, 1.6, 1.9 and 1.11  |                                  |         |

# 4.45 Providing psychological support for patients with relapsed cancer and their families

| To be able to provide   | e psychological support for patients with relapse | ed cancer and their famil | ies.  |
|---|---|---------------------------|-------|
| Level   |   |                           |       |
| Group A – Core  | Group B – Core                                    |                           |       |
| Group C – Core  | Group D – Advanced                                |                           |       |
| Knowledge   |   | Assessment<br>Methods     | GMP   |
| Discusses the proce and bereavement   | ss of accepting a terminal prognosis, grieving    | CbD, Final FRCR, mini-CEX | 1,2   |
| Discusses the role of the family, primary care, hospice, support groups palliative care teams, psychologist |   | CbD, Final FRCR, mini-CEX | 1,2,3 |
| Describes the indications for and side effects of antidepressants and psychotropic medication               |   | CbD, Final FRCR, mini-CEX | 1,2   |
| Describes cultural variation in ways of dealing with bereavement  |   | CbD, Final FRCR, mini-CEX | 1,2   |
| Skills  |   |                           |       |
| Supports patient and  | family to discuss the impact of the prognosis     | CbD. Final FRCR.          |       |

### Supports patient and family to discuss the impact of the prognosis CDD, Final FRCR, 1,2,3,4 and to cope with denial, anger, and emotional distress mini-CEX, PS Negotiates satisfactory outcome to requests by relatives for CbD, Final FRCR, 1,2,3,4 collusion to hide the prognosis from the patient mini-CEX, PS CbD, Final FRCR, Liaises with other professionals to develop a management plan 1,2,3,4 mini-CEX, MSF, PS CbD, Final FRCR, Prescribes appropriate medication 1,2 mini-CEX

### **Behaviours**

See sections 1.3, 1.4, 1.5, 1.6, 1.9, 1.11, 1.12 and 1.13

### 4.46 Co-ordinating social/financial support

To be able to co-ordinate social/financial support for patients with relapsed cancer.

### Level

Group A – Core Group B – Core Group C – Core Group D – Advanced

| Group C – Core Group D – Advanced  |                                  |         |
|--|----------------------------------|---------|
| Knowledge  | Assessment<br>Methods            | GMP     |
| Discusses the roles of other professional groups – social workers, occupational therapists, physiotherapists, GPs, district nurses, MacMillan nurses | CbD, Final FRCR,<br>mini-CEX     | 1,2,3   |
| Describes how to access financial support – attendance allowance under special rules   | CbD, Final FRCR, mini-CEX        | 1,2,3   |
| Skills   |                                  |         |
| Negotiates with the patient, family and other professional groups to develop an agreed package of care   | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |
| Behaviours   |                                  |         |
| See sections 1.3, 1.4, 1.5, 1.6, 1.9 and 1.11  |                                  |         |

# 4.47 Making clinical decisions in situations of uncertainty

| To be able to make clinical decisions in situations of uncertainty.                   |  |                                  |         |
|---|--|----------------------------------|---------|
| Level   |  |                                  |         |
| Group A – Advanced<br>Group C – Advanced  | Group B – Advanced<br>Group D – Advanced |                                  |         |
| Knowledge   |  | Assessment<br>Methods            | GMP     |
| Discusses the evidence base   |  | CbD, Final FRCR, mini-CEX        | 1,2     |
| Identifies the areas of uncertainty and methods of decreasing this                    |  | CbD, Final FRCR, mini-CEX        | 1,2     |
| Skills  |  |                                  |         |
| Evaluates the possible treatment options  |  | CbD, Final FRCR, mini-CEX        | 1,2     |
| Discusses options with patient and advises on the predicted benefits and side effects |  | CbD, Final FRCR, mini-CEX, PS    | 1,2,3,4 |
| Supports the patient to make a decision   |  | CbD, Final FRCR,<br>mini-CEX, PS | 1,2,3,4 |
| Behaviours  |  |                                  |         |
| See sections 1.3, 1.4, 1.5, 1.6, 1.11, 1.12 and 1.13                                  |  |                                  |         |